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Abstract 
Urinary tract infections (UTIs) are one of the most common bacterial 
infections worldwide with E. coli as the causal organism responsible for 75% 
of all cases (1). Uropathogenic E. coli (UPEC) naturally reside in the 
gastrointestinal tract (GI tract) and infect the urinary tract via migratory 
ascension of the urethra. Ethanolamine, an amino alcohol found naturally in 
phospholipids as phosphatidylethanolamine, can be metabolised by bacteria 
to be used as an alternate source of nitrogen and carbon (2). Within the GI 
tract ethanolamine provides pathogenic bacteria with a competitive 
advantage over the commensal bacteria (3, 4). The ability of bacteria to 
utilise ethanolamine is dependent on the presence of the ethanolamine 
utilisation (eut) operon encoding enzymes and bacterial microcompartment 
packaging (5). Recent studies suggest the regulator of the eut operon, eutR, 
can modulate the expression of virulence factors in Enterohaemorrhagic E. 
coli (EHEC) (6-8). Transcriptome analysis of UPEC in active UTIs has found 
that the eut operon is expressed within the urinary tract and confers a 
competitive advantage in the murine urinary tract, but the exact mechanism 
conferring this advantage is not known (9, 10).  
The aim of this thesis was to investigate the utilisation of ethanolamine by 
UPEC. This thesis provides evidence that ethanolamine is present in the 
urine at concentrations of approximately 0.57mM and correlated with the 
expression of the eut operon in UPEC infected urine. Additionally, the ability 
to metabolise ethanolamine by the eut operon is conserved across UPEC in 
this cohort (Cork University Hospital, Cork). Ethanolamine provides UPEC 
with a growth advantage as a sole nitrogen source in modified M9 minimal 
medium and an artificial urine medium (AUM). Metabolite analysis shows 
that the growth advantage observed in both media correlates with 
ethanolamine metabolism. Expression of eut operon genes and electron 
microscopy evidence of bacterial microcompartment formation was found in 
UPEC strain U1 metabolising ethanolamine in AUM.  Mutational analysis 
confirmed a requirement for a functional eut operon to metabolise 
ethanolamine and suggests that ethanolamine is utilised by UPEC as an 
additional carbon source. Ethanolamine provide U1 with a competitive 
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growth advantage at 10mM concentrations in vitro. RT-PCR provides 
evidence that suggests ethanolamine regulated the expression of type 1 
fimbriae in U1. In conclusion, this thesis supports the hypothesis that 
ethanolamine provides UPEC with a growth advantage in urine with a 
potential role in the pathogenicity of UTIs.
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Chapter 1  Ethanolamine Utilisation by UPEC in the 
Urinary Bladder.  
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1.1 Abstract  
Urinary tract infections (UTI) are a significant cause of morbidity and cause 
significant burden on health care systems worldwide. Escherichia coli is the 
leading cause of UTI with 75% prevalence (11). Uropathogenic E. coli 
(UPEC) are known to reside in the gastrointestinal (GI) tract and transition to 
the urinary tract to cause infections. UPECs have to adapt to the change in 
environment when transitioning into the urinary tract. To adapt to the urinary 
tract UPECs express virulence factors to aid colonisation and subvert the 
host immune response. Additionally, UPECs adapt their metabolism to utilise 
the limited nutrients available in the urinary tract (12).  
Ethanolamine is an amino alcohol that has found to be utilised by bacteria as 
a source of nitrogen and carbon (3, 13). Ethanolamine metabolism is 
mediated by the ethanolamine utilisation (eut) operon (5). Proteinaceous 
structures called bacterial microcompartments (BMC) encase the metabolic 
reaction protecting the bacteria from toxic intermediates (14, 15).  In addition 
to being metabolised, induction of the eut operon has been found to regulate 
the expression of virulence factors of pathogen in the gastrointestinal tract (7, 
8, 16). There is evidence that the eut operon is upregulated in urinary tract 
infection and promotes a colonisation advantage in the murine urinary 
tract(10, 17). It is however not understood whether this is to be utilised as a 
potential nutrient or whether it is utilised as a regulatory molecule.  
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1.2 Urinary Tract Infections 
Urinary tract infections (UTIs) result from the colonisation of the urinary tract 
by microbial pathogens. The human urinary tract is one of the most common 
sites for bacterial infection affecting 150 million people annually worldwide 
(18). In 2007 UTIs accounted for 10.2 million doctor visits in the United 
States, representing US$3.5 billion of economic costs from healthcare to time 
lost from work (11). Women have a higher risk of contracting UTI compared 
to men. This is attributed to the shorter length of women’s urethra and close 
proximity of the female urethra opening to the gastrointestinal (GI) tract (19). 
Almost 50% of all women will experience a UTI once in their lifetime, with 1 in 
3 women experiencing a UTI by the age of 24 (20). This is compared to 12% 
of men who are likely to experience a UTI in their lifetime. Around 20-30% of 
women who are diagnosed with a UTI will experience a second infection 
within 6 months of their primary infection (21, 22).  
UTIs are diagnosed by identification of clinical urinary symptoms and positive 
bacterial culture (>1x103 colony forming units per ml) (CFU ml-1)  (23). UTIs 
are categorised as either lower or upper urinary tract infection, being 
confined to the bladder (cystitis) or ascending into the kidney (pyelonephritis) 
(9, 11).  Additionally, UTIs are also categorised as either uncomplicated or 
complicated. Uncomplicated UTIs are typically seen in otherwise healthy 
individuals. Risk factors associated with uncomplicated UTIs include female 
gender, prior UTI, sexual activity, diabetes, vaginal infections, and genetic 
susceptibility (11). In contrast complicated UTIs occur in individuals who have 
compromised urinary tracts or immune systems, which include urinary 
obstruction, renal damage, pregnancy and the presence of foreign bodies 
such as indwelling catheters or other drainage devices (24). The most 
common cause of complicated UTI is the use of indwelling catheters, 
accounting for 70-80% of complicated UTIs in the USA (25). Additionally, 
catheter associated UTIs are the most common cause of secondary 
bloodstream infections (11).   
Gram positive and Gram negative bacteria can cause UTIs. These include 
Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Staphylococcus 
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saprophyticus and Enterococcus faecalis (11). Uropathogenic E. coli (UPEC) 
are the most common of these bacteria being responsible for 75% of all 
cases and 95% of all community acquired infections (1, 22, 26).  
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Figure 1.1. Pathogenesis of A. uncomplicated and B. catheter associated 
complicated urinary tract infections. In both situations uropathogen that reside in the 
GI tract contaminate the periurethral area and colonise the urethra before migrating into 
the bladder. Within the bladder A. uncomplicated UTI, colonise the bladder via pili 
mediated attachment, B complicated UTI, colonise the bladder by binding to fibronectin 
covered catheters. Neutrophils invade the bladder lumen to clear the infection, however 
bacteria are adapted to evade the immune system to replicate and form biofilm. Continual 
colonisation of the bladder results in epithelial damage and ascension to the kidneys.  
Adapted from Flores-Mires et al. 2015 (11) 
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1.3 Uropathogenic Escherichia coli (UPEC)  
As mentioned previously E. coli infections account for the majority of UTIs 
(1). E. coli is a Gram negative, rod shaped facultative anaerobe that is found 
to naturally colonise the lower gastrointestinal (GI) tract of mammals and 
reptiles (27, 28). The majority of E. coli in the gut reside as commensal 
bacteria forming part of the gut microbiota. While E. coli typically exists as 
commensal bacteria in 90% of the population, subtypes of bacteria have 
acquired virulence factors enabling E. coli to cause infection (28). E. coli 
exhibiting pathogenicity in the GI tract mainly cause diarrhoeal disease, and 
can be separated into: Enterohaemorrhagic E. coli (EHEC), 
Enteropathogenic E. coli (EPEC), Enterotoxigenic E. coli (ETEC), 
Enteroinvasive E. coli (EIEC), Enteroaggregative E.  coli (EAEC) (29).  
Another category of E. coli exists within the GI tract. These bacteria are 
believed to reside as commensals in the gut but have the ability to colonise 
other site within the body to cause infection. These are known as extra-
intestinal pathogenic E. coli (ExPEC) and are associated with urinary tract 
infections (UTIs), septicaemia, and neonatal meningitis (29).  
The variable nature of the E. coli genome is responsible for its ability to 
colonise a broad range of niches in mammals. The E. coli genome ranges in 
size from 4.6 to 5.6 Mbp (28, 30). With advances in sequencing over 60,000 
genes have been identified to make up the E. coli pangenome, the total 
number of gene identified in E. coli, and this number is estimated to rise as 
more E. coli are sequenced (31-34). Only 2100 genes make up the 
conserved core E. coli genome (33).  Therefore, most of the E. coli genome 
is highly variable between strains. E. coli can acquire genetic elements by 
horizontal gene transfer that encode fitness and virulence factors, which 
account for this variability of pathogenic strains compared to commensal 
(30). Consequently, pathogenic bacteria have the largest genomes when 
compared to K12 commensal. The UPEC strain CFT073 which has 13 
pathogenicity islands (PAIs) is one of the larger E. coli genomes sequenced 
to date (31). 
E. coli can be clustered into phylogenetic groups based on their genetic 
similarity. Seven phylogroups have been identified: Group A, B1, B2, C, D1, 
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D2 and E. E. coli strains can be separated into these phylogroups based on 
Multi Locus Sequence Typing (MLST) where the sequences of 6-8 
housekeeping genes are compared, and more recently by core genome 
sequence alignments (35, 36). There are limited phenotypic E. coli 
associations with different phylogenetic groups. For example, commensal 
strains mainly fall into phylogroups A and B2, and there is evidence to 
suggest a general trend towards increased prevalence of B2 commensals 
since the 1980s (28). Group A contains the K-12 lab strains such as 
MG1655. GroupB2, despite containing many commensal strains such as 
Nissle1917, also houses many ExPECs, including the well-characterised 
UPECs CFT073 and UTI89 (36). The majority of UPECs occupy phylogenetic 
group B2. E. coli that occupy group B2 and D have been termed ‘aggressive’ 
commensals, residing harmlessly in the gut however contain the most 
virulence genes, a characteristic of ExPECs (37, 38). 
1.3.1 Colonisation of the urinary tract  
For UPECs to establish infection in the bladder, they migrate from the GI 
tract into the urinary tract via the urethra (See Fig 1.1). Bacteria typically 
contaminate the periurethral area before they ascend into the bladder lumen 
via epithelial attachments (39).  Within the bladder, UPECs bind to and 
invade the bladder epithelial cells (BECs), via appendages on the bacterial 
cell surface (40, 41). As intracellular pathogens UPECs are able to evade the 
immune response and escape into the cytosol of host cells, to proliferate and 
form biofilm-like intracellular bacterial communities (IBC) (42). Epithelial cells 
respond to the formation of IBC by activating epithelial shedding, however 
this exposes underlying naïve epithelial cells to bacteria (11, 42). UPECs 
utilise this mechanism to infect exposed underlying transitional cells to form 
quiescent intracellular reservoirs (QIR) that can remain viable for months. It 
has been proposed that these QIR can be reactivated when transition cells 
differentiate into umbrella cells, and UPECs can then be released back into 
the lumen to cause secondary UTI (43). Additionally, UPECs are able to 
utilise motility mechanisms to ascend the ureters and colonise the kidney 
causing pyelonephritis (26, 29, 44). During prolonged infections, UPECs can 
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translocate through the renal pelvis and cause bacteraemia (11) (see Fig 
1.1).  
As UPECs transition from the GI tract to the urinary tract they have to adapt 
their metabolism and utilise virulence factors to overcome the nutritional and 
immunological challenges. While specific virulence factors have been shown 
to promote colonisation of the urinary tract by E. coli, there is no conserved 
set of genes that is specific to UPECs (38). Recent work has clarified the 
metabolic requirements for UPEC colonisation of the urinary tract (12, 45). In 
the urinary tract, urine is the primary source of nutrients encounter by the 
bacteria, with a very complex composition (46, 47). Compared to other host-
associated environments such as the gastrointestinal tract, urine is relatively 
nutrient poor, as arginine, methionine, valine, uracil, adenine, isoleucine and 
iron are in limited concentration, with a very low availability of sugars (1, 48). 
Despite the limited nutritional supply, UPECs have established ways to grow 
in this nutrient poor environment.(1, 49). A recent study has shown rapid 
UPEC growth in the urine following infection enhances survival in the urinary 
compared to other E. coli strains (50).  This implied rapid metabolic 
adaptation to the urinary tract is a key phenotype for UPEC pathogenesis.  
1.3.2 Adapting metabolism to the urinary tract 
UPECs in the bladder have to adapt from the nutritionally rich environment of 
the gut and utilise the limited nutrients in the urine to colonise the urinary 
tract. Within the GI E. coli preferentially reside within the nutrient rich 
environment of the mucus lining (51). In this environment E. coli faces 
competition for nutrients from other commensals and invading pathogens. E. 
coli preferentially utilise the mono- and di-saccharides within the mucus lining 
of the GI tract and cannot grow on complex polysaccharides as they lack the 
necessary hydrolysis enzymes (52). To overcome competition from other 
bacteria, E. coli have been found to utilise up to 6 limiting sugars at once to 
support colonisation of the GI tract (52). From mutational studies, glycolysis 
and the Entner-Doudoroff (ED) pathway are key for colonisation advantage of 
the E. coli commensal MG1655 (53). It has been found that gluconate, 
broken down by the ED pathway, is the first nutrient used by E. coli in the 
mouse intestine, therefore it is to be expected that mutants in this pathway 
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would result in a colonisation defect (54, 55). Commensal E. coli MG1655 
and EHEC strain EDL933 do not utilise the tricarboxylic acid (TCA) cycle and 
gluconeogenesis for colonisation in the streptomycin treated mouse intestine, 
an environment where there is no competition from other aerobic 
Enterobacteria (56). However, when the pathogenic strain EDL933 faces 
competition by commensal E. coli MG1655, it adapts its metabolism to use 
gluconeogenesis pathways rather than glycolysis and the ED pathway (56).  
When UPECs enter the bladder they rapidly adapt to the changing 
environment by altering their metabolism to the high-osmolality, moderately 
oxygenated, iron-limited environment that contains mostly amino acids and 
small peptides (49). Within urine UPECs utilise the TCA cycle and 
gluconeogenesis to generate energy from carbon, rather than glycolysis and 
ED pathway. This is due to the limited supply of mono- and di-saccharides in 
urine, except in diabetes (47). In the prototypical UPEC strain CFT073, 
mutations in the sdhB and pckA genes, that encode enzymes for the TCA 
cycle and gluconeogenesis pathway significantly reduce fitness in vivo in a 
murine UTI model (12). However, these pathways are dispensable in UPEC 
when residing in the GI tract, in favour of the ED pathway and glycolysis, 
therefore highlighting UPECs ability to adapt to utilises nutrients available in 
the distinct environments (53). 
Within the urinary tract, UPECs colonise different niches with differing 
nutrient availability by adapting its metabolism. During initial infection in the 
bladder, glycolysis is dispensable however as the infection ascends towards 
the kidneys, mutant UPECs deficient in the tpiA gene which is used in the 
glycolysis pathway have a colonisation defect in the mouse kidney (12). 
Additionally, when UPECs grow intracellularly they utilise sorbitol and β-
galactosides (57). Genes involved in the metabolism of sorbitol (srlA) and β-
galactosides (lacZ) were upregulated in wild type bacteria in a UTI mouse 
model and deficiencies in these genes leads to significantly smaller IBC 
compared to wild types (57).  
During in vitro growth in human urine, UPECs upregulate ddpA and oppA, 
genes encoding periplasmic peptide substrate-binding proteins. Deficiencies 
in producing these proteins leads to colonisation defects of UPECs grown in 
human urine (12). Other mutations affecting gluconeogenesis and 
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oxaloacetate for the tricarboxylic acid (TCA) cycle had similar effects, This 
suggest that amino acids and peptides in the urine represent the primary 
carbon source for UPECs during UTI (12). Additionally, while UPECs can 
utilise acetate as a source of carbon, it has been observed that the 
prototypical UPEC CFT073 utilises amino acids to produce acetyl-phosphate 
and subsequently acetate, but does not need to utilise acetate during murine 
UTI (58). This suggests that UPEC are adapted to acetogenic growth rather 
than assimilation. Peptide transport, the TCA cycle and gluconeogenesis are 
all necessary for UPEC colonisation of the urinary tract and up regulation of 
amino acid catabolic enzymes during growth in urine show the importance of 
amino acids and peptides as a source of carbon in the urine (12, 45, 59).  
D-serine is an abundant amino acid in urine, present at a concentration of 3-
40µg/ml, much higher than intestinal content (60-62). D-serine can be 
metabolised and used as a carbon source by some bacteria, however in the 
absence of a specific tolerance locus, intracellular uptake of D-serine is toxic. 
D-serine has also been found to be an important signalling mechanism to 
trigger expression of virulence genes. Deletion of the E. coli D-serine 
deaminase (dsdA), results in a prolonged lag phase when grown in human 
urine. In a competitive murine model this deletion was hypothesised to cause 
a hyper-colonisation phenotype (58). However, the latter phenomenon has 
been shown to be due to a non-isogenic mutant strain showing genetic 
rearrangement (63).  
Despite the high abundance of urea present in the urine that could provide a 
substantial nitrogen contribution, urine is thought to be a nitrogen limited 
environment for UPEC. This is because most E. coli lack the urease enzyme 
that hydrolyses urea to release ammonia (45).  Nitrogen is instead produced 
through the catabolism of amino acids and the glutamine synthase and 
glutamate oxo-glutarate aminotransferase system (GS/GOGAT). In vivo 
expression studies show that glnA, that encodes an enzyme involved in the 
GS/GOGAT, is up regulated in E. coli collected from infected urine (59). This 
system is upregulated to assimilate nitrogen when it is limited (64). Global 
transcription studies in urinary tract infection have shown that the 
ethanolamine utilisation (eut) operon is upregulated in urinary tract infection 
(17, 46). Ethanolamine provides EHECs with a source of nitrogen in the 
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bovine intestinal tract (3). Upregulation of the eut operon in infected urine 
implies it may be used as a nitrogen source during UTIs. This will be 
discussed further below.  
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Intestine (Commensal) Urinary tract (UPEC) 
Glycolysis TCA cycle 
Entner Doudoroff Amino acid metabolism 
 Gluconeogenesis  
 Sorbitol metabolism (IBC) 
 Galactoside metabolism (IBC) 
Table1.1 Summary of the metabolic pathways utilised in the intestine and 
the urinary tract.  
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Figure 1.2 Metabolic pathways utilised by UPECs in the urinary tract. 
Genes in blue are important for UPEC fitness. tpiA in red is important for kidney 
colonisation. (1) 
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1.3.3 Metal acquisition in urine  
Metal ions such as iron and zinc, are essential for bacterial metabolic 
functions and act as a co-factors for many enzymatic reactions.  During host 
infection bacteria must acquire metal ions and utilise many sequestering 
systems to compete with the host for essential metals.    
1.1.1.1 Iron 
Urine is an iron-limited environment with on average 1.3µM iron (47). E. coli 
have evolved to sequester iron in iron-limited environments by producing iron 
binding molecules such as siderophores and haemophores to facilitate Fe3+ 
uptake in the urinary tract. During urinary tract infection iron acquisition 
operons are among the most highly upregulated genes in UPEC compared to 
growth in vitro (17, 59, 65, 66).  E. coli encode four types of siderophores, 
low weight molecules that have a high affinity for ferric iron (Fe3+): 
enterobactin, aerobactin, yersiniabactin and salmochelin (67). It has been 
observed that UPECs produce all siderophores when residing in the gut prior 
to colonisation of the urinary tract. However salmochelin and yersiniabactin 
are produced in higher quantities in the urine compared to the intestine 
suggesting they have a greater role in urovirulence (67). Single mutational 
studies have found that uptake of aerobactin and yersiniabactin has greater 
effect on urovirulence than enterobactin and salmochelin (68). 
The primary iron regulator in UPEC is the iron sensing transcriptional 
repressor, Fur. In the presence of Fe2+ Fur binds to the fur box promotor 
region to prevent transcription of gene under its regulation. These include the 
siderophore operons, entD, entE, entCEBA and iucABCD which encode 
enterobactins and aerobactins respectively within UPECs (69). In iron limiting 
conditions Fur has low affinity for the fur box, therefore preventing repression 
of iron acquisition molecules (70).  
In addition to siderophores, iron is sequestered from haem, an iron-
containing porphyrin molecule, by secreted protein haemophores. Two outer 
membrane receptors ChuA and Hma mediate the uptake of iron from haem, 
and are both upregulated in iron limiting conditions in both human urine and 
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the mouse UTI model (71, 72). ChuA is assumed to be a favoured haem 
receptor as mutants in ChuA are outcompeted by Hma mutants, however 
absence of either of these receptors leads to a fitness defect in the mouse 
UTI model (72). Additionally ChuA plays a function in IBC formation by UPEC 
as ChuA is upregulated in IBC infected epithelial and lack of ChuA results in 
smaller IBC (66).    
Iron-bound molecules are transported into bacterial cells by utilising the 
TonB-ExbB-ExbD complex. Proton motive force mediated by ExbB and ExbD 
activity energises TonB which provides the energy for the iron receptor on 
the surface to translocate iron-bound complexes into the periplasm (70, 73). 
ATP-binding cassettes then translocate the molecule into the cytoplasm. In 
vivo experiments have found that TonB mutants have fitness deficiency 
compare to the wild type in the mouse model (74).  
The host immune system blocks UPEC uptake of siderophores by secreting 
lipocalin-2 (LCN-2). Neutrophils and epithelial cells secrete LCN-2 in 
response to TLR-mediated bacterial recognition (75). LCN-2 specifically 
binds iron-bound enterobactin to prevent binding to surface bacterial uptake 
receptors. However UPEC overcome this host defence by producing 
glycosylated enterobactin, termed salmochelin (67). Salmochelin production 
requires the iroA operon iroBCDEN which encodes glycosyltransferase 
(glucotransferase) iroB. Glycosylation of enterobactin prevents host LCN-2 
recognition and binding, giving these bacteria a distinct advantage (76, 77).  
1.1.1.2 Zinc  
In addition to iron requirements, zinc is an essential metal for bacterial 
survival. There are two main uptake systems utilised by UPECs to import 
zinc. The first is the ABC transporter ZupACB and the second is the 
permease ZupT (70). The Znu transport system (ZupACB) is a zinc specific 
transporter while ZupT can also facilitate the import of Fe2+, Mn2+ and Co.  
Mutational studies have found that the Znu transport system is the primary 
method of zinc uptake and that ZupT has a secondary role (78). While 
UPECs are able to colonise the urinary tract in the absence of ZupACB , 
numbers are severely reduced (78). It is known that during acute infections 
neutrophils produce calprotectin which binds zine and calcium ions, however 
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UPEC do not have increased virulence in calprotectin deficient mice (79). 
Therefore, calprotectin does not appear to have an obvious protective role 
against UPEC. 
1.1.1.3 Copper 
Copper ions and haem form the catalytic core of cytochrome bo terminal 
oxidase (cyoABCD) which is involved with aerobic respiration in bacterial 
cells (70). Copper however is biocidal to bacteria when in excess and there is 
a recent hypothesis that neutrophils or other aspects of the innate immune 
system use copper ions to kill bacteria (80). Cu+ can generate very toxic 
hydroxyl radicals which can damage iron-sulphur clusters in the cell and 
inactivate dehydratases, which are important in the synthesis of branched 
chain amino acids and other reactions (81). To counteract the toxic effect of 
copper, UPECs utilise copper efflux systems. There are three main systems 
in UPECs CopA, CueO and CusCFBA, which are expressed dependent on 
the severity of toxicity. CopA is active in low toxicity conditions, CueO is 
activated with CopA in moderately toxic conditions and finally the CusCFBA 
which is active during severe toxicity and low oxygen conditions (82-84). 
Within infected urine copper was measured at 287nM compared to 59nM in 
healthy urine, which supports the recent hypothesis that immune cells use 
copper ions to eliminate bacteria (80). In the study the cus system was highly 
upregulated in UPEC in infected urine compared to growth in sterile urine in 
vitro, and in vivo cus mutants had a colonisation deficiency in the murine 
model (17) demonstrating the importance of copper efflux in UTIs. In 
contrast, cueO deletion mutants had a colonisation advantage in mouse 
model by facilitating the influx of Fe2+(85).  
1.3.4 Colonisation factors 
UPEC, like other bacteria have short filamentous organelles called fimbriae 
that allow the bacteria to adhere to various surfaces. UPEC carry significantly 
higher number of fimbriae genes in their genome compared to faecal and 
commensal strains, with the highly characterised CFT073 containing 12 
fimbriae gene clusters in its genome (86). There are many types of fimbriae 
produced by UPEC including type 1, P, F1C, F9 and Auf. Type 1 and P 
fimbriae are the best characterised bacterial fimbriae (86).  
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Type 1 fimbriae encoded by the fim operon are conserved in E. coli. Within 
the urinary tract type 1 fimbriae mediate adhesion to BECs via the fimbriae 
binding protein FimH. FimH binds mannosylated glycoproteins, uroplakin 
(UP) Ia and IIIa on superficial facet cells and α1β3 integrin found on the 
surface of the naïve transitional epithelial cells (40, 87). Adhesion of UPEC to 
the epithelial cell wall via FimH prevents the expulsion of bacteria by shear 
force stress created by urination (88). In addition, FimH mediates invasion of 
the bladder epithelium by UPEC to create intracellular bacterial communities 
(IBC). Binding to the BECs activates Rho GTPase, which initiates actin 
rearrangement within the epithelial cell and internalisation of the UPEC (41, 
89, 90). Expression of type1 fimbriae in urine is tightly regulated by several 
global regulatory proteins controlling the orientation of an invertible element 
carrying the promoter region (9). This promoter is inverted to the ‘ON’ 
orientation in the presence of FimB recombinase and locked in the ‘OFF’ 
orientation in the presence of FimE recombinase.  
Type 1 fimbriae are conserved in UPEC and are considered essential in the 
development of UTIs in murine and human investigations. The fim operon is 
highly expressed in UPEC isolated from the murine urinary tract and fim 
mutants do not colonise the mouse urinary tract (59, 91). However, it is 
notable that, when gene expression in bacteria isolated from infected human 
urine was analysed, components of the fim operon were detectable in less 
the 50% of the urine samples collected (46, 65).  
P fimbriae or pyelonephritis-associated fimbriae are unique to uropathogenic 
E. coli, encoded on pathogenicity islands distributed amongst UPEC and 
most commonly associated with pyelonephritis strains (9). The adhesion 
PapG mediates binding to glycosphingolipids on renal epithelium. Expression 
of the P fimbriae is controlled by the methylation of the promotor region 
papAB. However, deoxyadenosine methylase which mediates the 
methylation of the promotor region, is competitively blocked by the leucine-
responsive regulatory protein (Lrp), which binds to the promotor region 
preventing methylation and therefore transcription (9).   
E. coli preferentially form one type of fimbriae at a time (92). Cross talk 
between fimbriae operons in a single strain of E. coli can lead to variable 
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expression of the different fimbriae (93). This is a process known as phase 
variation and can give rise to subpopulations of UPEC expressing 
functionally distinct fimbriae increasing the probability of adherence (94). 
Additionally mutational studies have found that in the absence of the 
preferred type 1 fimbriae and P fimbriae, UPEC express alternative fimbriae 
to retain colonisation of the urinary tract (94).  
19 
 
 
 
 
 
Figure 1.3 Pathogenic mechanism of Uropathogenic E. coli attachment and 
invasion of bladder epithelial cells. Type 1 pili mediate attachment to the 
superficial BEC via uroplaking Ia and IIIA. Invasion of the UPECs into epithelial 
cells is controlled by Rho GTPase activated actin rearrangement and once 
within the cells UPECs form intracellular bacteria communities (IBCs). Toxins 
released by UPECs in sublytic concentration can lead to cell apoptosis and 
exfoliation, exposing underlying epithelial cells to bacteria invasion. UPECs can 
form quiescent intracellular reservoir (QIRs) which are involved with recurrent 
infections. Adapted from Croxen and Finlay 2010 (29).  
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1.3.5 Motility  
Flagella are appendages produced by E. coli and other bacteria to facilitate 
motility. Transcriptome studies have shown that fliC, a major flagellin protein 
is not expressed during acute cystitis (17, 59, 65). However GFP-tagged FliC 
is highly expressed in the ureter in the mouse model (44). This suggests 
flagella are important for the progression of UPEC into the kidneys, and is 
confirmed by a mutational study found that fliC mutants successfully colonise 
the bladder however they do not ascend to the kidneys (95). Within the 
kidney flagella also mediate the invasion of UPEC into the renal epithelium 
(96). As the need to bind to epithelial cells and move in the urinary tract are 
conflicting it has been suggested that there is interplay between fimbriae and 
flagella operons. Lane et al. found that expression of the fim operon 
decreases the expression of flagella, while overexpression of the flagella 
gene flhDC in UPECs does not prevent expression of type 1 fimbriae (97). 
This suggests that expression of the fim operon expresses a unidirectional 
repression on flagella-mediated motility in UPEC. Further investigations have 
found that ‘X’ genes located in fimbriae operons, in particular papX and focX, 
repress the expression of the flagella regulator flhDC (98).  
1.3.6 Toxins 
Some secreted toxins that cause tissue damage and inflammation are 
encoded by UPEC. Well characterised examples include α-haemolysin 
(HlyA), cytotoxic necrotising factor-1 (CNF-1), secreted auto-transporter toxin 
(Sat) and vacuolating transporter protein (Vat) (11, 26). 
HlyA toxin is encoded by around 50% of all UPEC and expression of the 
toxin is associated with increased clinical severity (26). HlyA at high 
concentration integrates into the cholesterol environments in the host cell 
membrane in a Ca2+ dependent process, to create pores in the cell 
membrane (11). Pore formation promotes lysis of cells, releasing iron and 
nutrients. Upregulation of hlyA in IBC suggest that HlyA is important for 
intracellular survival (66). In addition to its cytolytic activity, when present in 
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sub-lytic concentrations, HlyA is involved with communication between host 
and pathogen by modulating signalling pathways within the host cell. Sub-
lytic concentrations of HlyA can modulate the immune response such as 
suppressing the pro-survival signal pathways, NF-kB and Akt, which 
increases cell apoptosis and epithelial shedding (99, 100).  
CNF-1 is encoded by approximately one third of UPEC isolates (26). Once 
secreted by the bacteria CNF-1 enters the host cells via endocytic vesicles 
(101). Within the host cells CNF-1 disrupts Rho GTPases signalling by 
constitutive activation. This disrupts the cytoskeleton leading to formation of 
actin stress fibres, lamellapodia, filopodia and induction of membrane ruffling, 
which increases bacteria uptake (26). In addition to these morphological 
changes, CNF-1 disrupts immune pathways and increases epithelial cell 
shedding.  Absence of CNF-1 has been associated with decreased fitness in 
the murine UTI model therefore highlighting the importance of CNF-1 in 
UPEC infection (102).  
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1.4 Host Defences Against UTIs 
Despite the bladder’s close proximity to the densely populated GI tract, the 
bladder remains mostly infection free. The anatomy and physiology of the 
bladder prevent the pathogenic colonisation of the urinary tract. The bladder 
is lined by a mucus membrane, comprised of a layers of epithelial cells 
covered with a thin lining of glycosaminoglycan forming a barrier over the 
epithelial cell and deters bacteria attaching to the apical surface of the 
epithelium (103, 104). 
Urine held within the bladder provides a potential growth medium for bacteria 
in the bladder (50). However, the shear force of urine flow expels bacteria 
before they can establish colonisation. UPEC have adapted to circumvent the 
effects of shear force through epithelial attachment. Both type1 and P 
fimbriae can utilise the shear force of urination to strengthen their attachment 
to the bladder epithelium surface and generate resistance to detachment 
from the force needed to unravel their typical helical structure (88).  
1.4.1 Epithelial response  
If bacteria persist in the bladder they encounter the innate immune response 
mediated by epithelial cells. 90% of the apical surface of the epithelium is 
covered in urothelial plaques, proteinaceous scallop-shaped membrane 
plaques assembled from uroplakins (UPs). These plaques, create a physical 
barrier, which discourages the attachment and invasion of most bacteria 
(105).  UPEC however utilise UP Ia/IIIa as receptor for type 1 fimbriae to 
facilitate colonisation (87).  
Invading pathogens are recognised by pattern receptor receptors (PRR) on 
the epithelial cell such as toll like receptors (TLR) TLR-4, TLR-5 and TLR- 11. 
Recognition of lipopolysaccharides (LPS) and flagella on the bacteria surface 
mediate the secretion of cytokines and chemokines such as interleukin-6(IL-
6), IL-1β and IL-8 from the epithelium (106, 107). These are the first 
cytokines detected in the urine after infection and activate an influx of 
immune cells to eliminate the offending pathogen. Antimicrobial peptides 
23 
 
(AMPs) are also secreted by the epithelium which can directly target the 
bacteria and eliminate them from the urine (108, 109). The mRNA of human 
cathelicidin, LL-37,  is detected in the urine within 5 minutes of BEC 
stimulation with UPEC, and deficiency in LL-37 secretion has been 
associated with increased UPEC load in the murine urine (108). β-defensin, 
another AMP is primarily secreted from kidney epithelial cells (109). 
Secretion of both AMPs contributes to cytokine production and subsequent 
neutrophil recruitment to the bladder (110).  
As part of the function of the bladder, it has to expand and contract 
depending on the volume of urine contained. The cells in contact with urine 
are called umbrella cells which cyclically change their surface area 
transforming from an inverted umbrella parasol shape in voided empty 
bladders to flat and squamous shaped in filled bladders (111). Fusiform 
vesicles assist with the recycling of the epithelial membrane, in particular 
there are large pools of the fusiform RAB27b in the umbrella cell epithelium 
(112). When urine enters the bladder the fusiform vesicles exocytose into the 
umbrella cell membrane in a cAMP dependent manner to provide the extra 
membrane for bladder distension and as the bladder empties, intracellular 
fusiform vesicles form by internalising the RAB27b membrane (112, 113). 
UPEC have exploited this pathway to gain entry into the epithelial cells (113). 
TLR-4 receptors within the fusiform vesicle detect the invading bacteria and 
proceed to expel the bacteria (114). Over 80% of bacteria are expelled from 
the epithelium after 24 hours but the remaining bacteria are able to multiple 
and form intracellular communities (113). When the bladder epithelium 
become overburdened with bacteria the epithelial cells undergo cell death 
and shedding of epithelial occurs to eliminate bacteria from the bladder (42, 
115). Shedding the apical layer of the epithelium however exposes the 
underlying naïve cells to the bacteria remaining in the urine (42).  
1.4.2 Neutrophils, mast cells and macrophages 
Neutrophils are the first immune cells recruited to the bladder after bacteria 
have been detected in the bladder and the presence of white cells in the 
urine is a hallmark for urinary infection. In response to IL-8 and TNFα 
secretion from the epithelium, and TNFα secretion from mast cells (see 
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below) neutrophils migrate through the epithelium (116, 117). The secretion 
of matrix metalloprotease-9 (MMP-9) by the neutrophils facilitates their ability 
to penetrate the basement membrane (118). Neutrophils have been found to 
be present in the bladder within 2 hours of infection and peak at around 6 
hours post infection (119). They play an important role in bacterial clearance 
and deficiency in neutrophil recruitment increases susceptibility to UTI and 
decreases ability to clear infection in mice (120). Neutrophils clear infection 
by engulfing and degrading the bacteria intracellularly. To facilitate this 
mechanism, neutrophils secrete pentraxin 3 (PTX3), which acts as an 
opsonin to coat the invading bacteria (121). The release of neutrophils 
however can have detrimental effects in the urinary tract, as the release of 
reactive oxygen species and other cytotoxic products including 
cyclooxygenase 2 (COX2) causes inflammatory damage to the bladder tissue 
and could predispose the bladder to persistent infection (122).  
In addition to neutrophils, mast cells and macrophages are important cellular 
defences in the bladder. Mast cells are the most prominent resident innate 
immunity cell in the urinary tract, and reside in the lamina propria of the 
bladder. Within the first hour of infection, histamine and other 
proinflammatory molecular normally located in the granules of mast cells are 
detected in the urine (123). TNFα is one of the pro-inflammatory molecules 
secreted by mast cells and aids in recruitment of neutrophils to the bladder. 
When mast cells are deficient, bacterial clearance is limited (117). In addition 
to promoting inflammation, mast cells are important in establishing 
homeostasis and tissue recovery. It was recently reported that several hours 
into an immune response, mast cells abruptly express the 
immunosuppressive cytokine IL-10 (117). This coincides with epithelial 
shedding, and therefore the need to replenish the epithelial layer, a process 
that cannot happen during active inflammation.  Expression of IL-10 however 
can result in the premature resolution of inflammation which can leave a 
residual bacterial community and cause subsequent infections(117).  
Macrophages also play a critical role in the neutrophil response in the 
bladder. A sub population of macrophages reside in the mucosal lining of the 
bladder. Upon infection macrophage produce cytokines to drive an 
inflammatory response. In particular the resident macrophages (mainly 
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LY6C) secrete CXCL-1 and CXCL-2 to recruit neutrophils and LY6C+ 
macrophages into the bladder. LY6C+ macrophages are essential for 
neutrophil migration through the basement membrane (118). TNFα secreted 
by recruited LY6C+, causes the resident macrophages to secrete CXCL2 
which in turn activates the release of MMP-9 (124). Therefore, macrophages 
aids in the control of the neutrophil response in the bladder.  
1.4.3 Bladder microbiome 
Until the advancement of culture-independent methods to detect bacteria, the 
healthy urinary tract was believed to be sterile. Studies as early as 2004 
identified non-cultured bacteria in individuals who had no previous episode of 
urinary tract infection (125). Clean- catch urines from asymptomatic healthy 
women have been found to contain  more than 45 genera across 11 different 
phyla (126). There is much variation in bacteria genera described for the 
urinary microbiome, however Lactobacillus and Streptococcus have been the 
most frequently genera reported in the urinary microbiome (127). These 
species have been associated with protective functions.  
The urinary microbiome has been observed to vary depending on sex and 
age (128, 129). Lewis et al., found that Jonquetella, Proteiniphilum, 
Saccharofermentans and Parvimonas were only present in individuals over 
the age of 70, however there are species in the urinary microbiome that are 
present independent of age (128). In regard to differences between sex, 
women were found to have predominately Lactobacillus species, while 
Corynebacterium were the predominant species in men (129). However 
cautious interpretation of this data is required due to the likely contamination 
of urine from female patients from the resident microflora of the urogenital 
tract in clean-catch specimens. 
In the gut, the resident microbiome protects the host from infection (130). 
Therefore it could be hypothesised that a bladder-resident microbiome could 
provide the same protection, especially with the identification of 
Lactobacillus, a genus that is considered beneficial in both the intestine and 
the vagina (131). However, evidence for a function of resident urinary 
microbiome in protection against UTI is currently lacking.  
26 
 
1.5 Ethanolamine Utilisation 
Ethanolamine is an amino alcohol that is present in mammalian and bacterial 
cell membranes in the form of phosphatidylethanolamine (PE) (132, 133). PE 
is the most abundant phospholipid in prokaryotic cells and the second most 
abundant phospholipid in eukaryotic cells after phosphatidylcholine (132). 
Phosphodiesterases break down PE to release glycerol and ethanolamine 
that can then be utilised by bacteria and E. coli encodes phosphodiesterases 
required for the breakdown of PE to ethanolamine (134, 135).   
The animal gut is an abundant source of ethanolamine due to the high 
turnover of enterocytes (25% per day), bacterial presence and the host diet 
(136).  A concentration of over 2mM of ethanolamine was measured in 
bovine intestinal content and between 0.5mM and 1mM of ethanolamine has 
been detected per gram of homogenised colon (3, 4). Recent metabolome 
studies have detected ethanolamine in serum at a concentration of 2µM and 
in the urine at a mean concentration of 37.0 µM/mM creatinine in urine from 
20 healthy adult subjects (approximately 500 µM) (47, 137). Ethanolamine 
can be used by bacteria as a valuable source of nitrogen and carbon, and 
within the intestine the ability to metabolise ethanolamine has been found to 
provide pathogenic bacteria with a competitive advantage (3, 4).  
1.5.1 Ethanolamine utilisation operon 
The best documented route for ethanolamine utilisation by bacteria is via 
activation of the ethanolamine utilisation (eut) operon. The eut operon was 
first identified as a 17-gene operon in Salmonella enterica Serovar 
Typhimurium (S. Typhimurium) (5). Comparative genomic analysis has now 
revealed that a form of the eut operon is conserved in 100s of species of 
bacteria across the phyla Proteobacteria and Firmicutes (138). The gene 
content of these operons however differs with some species only containing 
a ‘short operon’, encoding core enzymes while other species contain a ‘long 
operon’ which in addition encodes structural genes for bacterial 
microcompartments. All taxa containing a form of the eut operon conserve 
eutB and eutC, which together comprise the two subunits of the 
ethanolamine ammonia lyase enzyme, suggesting that these genes formed 
the earliest version of the operon (139).  
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E. coli and S. Typhimurium, encode a 17-gene eut operon (5)(Fig 1.4). In 
addition to the enzymes required for ethanolamine metabolism, the operon 
encodes regulatory proteins, structural proteins that form a bacterial 
microcompartment (BMC) and substrate transport proteins (5).  This form of 
the eut operon is under the control of the regulatory protein EutR. Studies in 
S. Typhimurium have found that all of the eut genes are under the control of 
one upstream promotor P1, which is activated by the binding of EutR with the 
cofactors ethanolamine and adenosyl cobalamin (AdoCbl) (7, 13, 140). eutR 
is located at the distal end of the eut operon and is preceded by the low-level 
constitutive promotor P2 (13, 141). The location of eutR in the operon creates 
a positive feedback loop increasing the amount of eutR (141). Biochemical 
studies have found that EutR binds to P1 in the absence of ethanolamine and 
AdoCbl, however it is only with these co-factors that the operon is expressed 
(7).  It has been found when EutR is present in high levels, that the operon 
can be activated in the presence of only one co-factor (141).  In addition to 
EutR the ethanolamine ammonia lysase requires AdoCbl for activity (see 
below), therefore autoregulation of the eut operon EutR to effectively 
compete with the ethanolamine ammonia lysase for AdoCbl  and maintain 
expression of the operon (140). 
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Gene  Function   
eutR Transcriptional Regulator  (141) 
eutB Ethanolamine ammonia lyase large subunit (139) 
eutC Ethanolamine ammonia lyase small subunit (139) 
eutE Aldehyde oxidoreductase (2) 
eutD Phosphotransacetylase (5) 
eutG Alcohol dehydrogenase (2) 
eutJ Putative chaperone protein (5) 
eutT Corrinoid cobalamin adenosyltransferase (5) 
eutH Transport protein (2) 
eutA Reactivating factor (5) 
eutQ Ethanolamine utilisation protein (5) 
eutP Ethanolamine utilisation protein (5) 
eutM BMC shell protein  (5) 
eutN BMC shell protein (5) 
eutK BMC shell protein (5) 
eutL BMC shell protein (5) 
eutS BMC shell protein (5) 
 
Figure 1.4 Organisation of eut operon in E. coli. 15Kb operon (not to 
scale).  
Table1.2 Function of genes in the ethanolamine utilisation operon 
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1.5.2 Metabolism  
Ethanolamine is metabolised in a two-step enzymatic reaction to produce 
ammonia, acetyl coenzyme A (Co-A) and acetate (13, 142, 143) (Fig 1.5). 
Ethanolamine is hydrolysed by the ethanolamine ammonia lyase enzyme 
(EAL) encoded by eutB and eutC to produce ammonia and acetaldehyde 
(144). This reaction is dependent on the cofactor AdoCbl (143) which is 
produced from the adenosylation of cobalamin (B12) by EutT, a cobalamin 
adenosyl transferase (145). The breakdown of ethanolamine by the EAL 
irreversibly cleaves the C-Co bond in the co-factor AdoCbl inactivating the 
enzyme. EutA is a reactivating factor which removes the damaged co-factor 
from the enzyme allowing a new AdoCbl molecule to bind (146).  
Acetaldehyde is converted to acetyl-CoA by the acetaldehyde 
dehydrogenase, EutE (5, 13).  Acetyl-CoA can be used in a number of 
metabolic reactions including the TCA cycle, the glyoxylate cycle or lipid 
biosynthesis. Some Acetyl-CoA is converted by EutD into acetyl-phosphate 
before going on to form acetate via the acetate kinase enzyme (147, 148). 
There is some dispute in the necessity of EutD in the utilisation of 
ethanolamine as a carbon source (15, 148).  It is agreed that EutD is needed 
to recycle Co-A and generate acetate which can be recaptured when bacteria 
required energy. Penrod and Roth however attribute  the necessity of EutD, 
to prevent build-up of acetyl-coA and acetaldehyde (15), while Starai et al. 
believe that the conversion of acetaldehyde to ethanol by the action of EutG 
can prevent toxic build-up of acetyl-coA and acetaldehyde (148).  
EutG, an alcohol dehydrogenase, converts acetaldehyde to ethanol. 
Stojiljkovic et al. have demonstrated that EutG is needed by most bacteria to 
utilise ethanolamine as a carbon source and in some cases as a nitrogen 
source (2). As mentioned above it has been suggested that EutG is used as 
a mechanism to prevent the toxic build-up of acetaldehyde (2, 133).  
Additionally, EutG can convert acetaldehyde to ethanol to maintain a redox 
balance by recycling NADH to NAD+.  However  as this can also be achieved 
through respiration it is not assumed to be an essential role of EutG in most 
conditions (5).  
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Other accessory proteins that are involved with ethanolamine metabolism 
include EutH, a transporter protein that translocates ethanolamine across the 
bacterial membrane in acidic pH (149). The function of proteins encoded by 
eutJ, eutP and eutQ are less clear. Mutational studies have found that EutJ is 
needed to utilise ethanolamine as a carbon source but is dispensable for 
utilisation as a nitrogen source. It has been postulated by Stojiljkovic et al. 
that EutJ is a chaperone for EutE and EutG (2). In S. Typhimurium EutP and 
EutQ have recently been shown to have acetate kinase activity, which is 
required for the growth of S. Typhimurium in anaerobic conditions (150). 
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Figure 1.5 Schematic representation of the Eut metabolosome or bacterial 
microcompartment A. metabolism of ethanolamine within the microcompartment B. 
arrangement of shell protein in the eut bacterial microcompartment. (151) 
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1.5.3 Bacterial microcompartments  
Ethanolamine metabolism in E. coli and other Enterobacteriaceae occurs 
within proteinaceous organelle-like structures called bacterial 
microcompartments (BMC) in the cytoplasm (5). These structures are around 
100-200nm in diameter and form distinct polygonal shapes (152). They were 
first observed by Drews and Niklowitz in the 1950s in cyanobacteria using 
electron microscopy (153). Twenty years after BMCs were first identified in 
cyanobacteria it was found these proteinaceous structures were filled with 
RuBisCO and play an important role in carbon fixation, and were then known 
as carboxysomes (154). Since their initial discovery, homologues of 
carboxysome structural proteins have been identified in diverse operons in 
bacteria, and at least 23 different type of BMCs are known to facilitate 
anabolic reactions (e.g. carboxysomes) and different catabolic processes 
(metabolosomes) (155). These include catabolism of 1-2 propanediol (pdu 
operon) and ethanolamine (eut operon) (2, 154, 156, 157). Unlike 
carboxysomes, metabolosomes are not constitutively expressed and are only 
assembled in the presence of their specific substrate (13, 156). 
The basic structure of BMC is conserved across all types of BMC where a 
thin enclosing shell is composed of small protein subunits. Protein crystal 
structures have allowed the classification of the protein subunits belong to 
three categories of shell proteins first identified in carboxysomes in 1994 
(158). Subsequently they have been identified in the genome of many 
bacteria such as in the pdu operon and eut operon of Salmonella sp and the 
eut operon of E. coli (5, 138, 156). BMC shell proteins are on average 90 
amino acids in length and mainly form cyclic hexamers which assemble 
together to form the basic structure of the BMC (157). The three types of 
BMC shell proteins that have been identified and are essential for functional 
shell assembly are: BMC-H, which are the most numerous, contain one copy 
of the Pfam domain PF00936 and form cyclical hexamers; BMC-T which 
contains two copies of PF00936 (tandem domain) and form trimers 
(pseudohexamers); and a BMC-P, the least abundant, which contains the 
domain PF03319 and form cyclic pentamers (159, 160). BMC-H and BMC-T 
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form molecular sheets through antiparallel association of lysine residues 
conserved across all PF00936 domains. BMC can form in the absence of 
BMC-P which have been hypothesised to close the BMC at the vertices of a 
polygonal structure, however these structures are presumed to be highly 
porous (161). BMC-P pentamer proteins, also known as BMC vertex proteins 
(BVP), are positioned at the vertices of the BMC and guide the formation of 
the typical icosahedral configuration of carboxysomes. Electron microscopy 
has found that pdu BMC form polyhedral shapes in vivo but these are not 
obviously icosahedral. A small recombinant very regular microcompartment 
shell has been completely crystallised and the interrelationships of the 
different BMC proteins are precisely known for this structure (162). 
Individually cloned BMC-H and BMC-T proteins have the ability to form long 
tube like structures (163). Less is known about the structure of the eut 
microcompartment, however they are assumed to form polyhedral shapes 
similar to the pdu BMC as the operon also encodes a BMC-P pentamer 
protein (5). Identification of five BMC protein resembling carboxymsome shell 
proteins were identified in the eut operon of S. Typhimurium (5). These are, 
EutS, -M, -N, -L and –K. EutN forms a pentameric structure with other the 
BMC proteins in the eut MCP. Despite being identified genetically there are 
few images of eut BMC particularly in E. coli (164, 165) 
While the presence of the BMC and reactions that occur within BMCs have 
been identified, the role of the protein shell is less clear. In metabolosomes 
such as the pdu BMC and eut BMC, it has been postulated the structure of 
the BMC protects the bacteria from the toxic aldehyde intermediates 
produced in the metabolism of 1, 2-propendiol and ethanolamine (2, 166). By 
enclosing them in a protein shell, it drives the production of non-toxic 
compounds through the action of downstream enzymes such as aldehyde 
dehydrogenase eutE and alcohol dehydrogenase eutG in the eut BMC (14). 
An alternate hypothesis for the function of BMC implies that the BMC 
functions to prevent the loss of these volatile aldehyde intermediates from the 
cell (15). By retaining the aldehyde intermediates, metabolism can be driven 
forward to produce acetyl-CoA or produce acetate which can be recaptured 
later. When the formation of the eut BMC is disrupted in S. Typhimurium, 
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ethanolamine cannot be utilised as a carbon source, and high excretion of 
acetaldehyde is detected (15).  
1.5.4 Ethanolamine utilisation and pathogenicity  
The eut operon is widely distributed in bacterial species with many of them 
residing in the mammalian gastrointestinal tract (138). These include the 
pathogenic and commensal bacteria in the genera Listeria, Salmonella, and 
Clostridium, pathogenic and commensal strains of Escherichia coli and the 
commensal strains of the genus Enterococcus (138). Genome analysis and 
literature mining however has associated the metabolism of ethanolamine 
with gastroenteritis (138, 167). This has been supported by enteric 
colonisation studies detecting expression of the eut operon in animal models 
(168, 169).  
As ethanolamine can be broken down to be used as a source of nitrogen or 
carbon, it is hypothesised that ethanolamine provides eut-operon containing 
bacteria with a nutritional advantage.  Bertin et al. measured 2.2mM 
ethanolamine in the bovine GI tract and found that EHEC strain O157:H7, a 
zoonotic pathogen which has been associated with large food poisoning 
outbreaks, utilises ethanolamine as a nitrogen source. This provided a 
competitive advantage over commensal bacteria in bovine intestinal content 
in vitro (3). Mutational studies have found that Listeria monocytogenes 
deficient in key enzymes in the metabolism of ethanolamine have reduced 
colonisation of host models (168, 170). Additionally, S. Typhimurium can 
utilise ethanolamine to provide a colonisation advantage in the gut during 
acute infection. This however is dependent on the presence of the final 
electron acceptor tetrathionate that is produced during inflammation in the 
gut to allow ethanolamine to be respired (4, 171, 172). Surprisingly, in the 
Clostridium difficile hamster model, the ability to metabolise ethanolamine 
does not enhance colonisation of the gut, but provides a protective role for 
the host, delaying the progression of disease, compared to mutants in eutA 
(173). While ethanolamine has been predicted to be utilised by pathogens 
providing them with a source of ethanolamine, a recent study has found that 
commensal E. coli can also utilise ethanolamine and that metabolising 
ethanolamine provides the commensals with a competitive advantage over 
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pathogenic E. coli O157:H7(174). However this competitive advantage was 
seen in minimal media, while O157:H7 held a competitive advantage over 
commensals when grown in bovine intestinal rumen, therefore further 
investigation in complex media would be needed (3).  
There is evidence to suggest that ethanolamine has a role in pathogenesis 
beyond metabolism. In a study in S. Typhimurium, there was a colonisation 
defect in eutB mutants in the murine infection model, however this deficiency 
was more severe in eutR mutants and reduced the progression of the 
disease in this model (16). S. Typhimurium is a facultative intracellular 
pathogen that invades macrophage as part of its colonisation. The ability to 
survive within macrophages depends on the expression of type three 
secretion systems (T3SS) which are encoded on Pathogenicity Island- 2 
(SPI-2)(175). Anderson et al. has found that EutR regulates the expression of 
SPI-2 by directly binding to the SPI-2 regulator ssrB (16). Like S. 
Typhimurium, the eut operon acts as a signalling molecule in EHEC. In 
EHEC, ethanolamine has been implicated in the expression of the LEE 
operon, which is responsible for the attaching and effacing lesions in the 
colon characteristic of EHEC infection (7). Ethanolamine and B12 dependent 
transcription of eutR activates the LEE operon by binding directly to the ler 
regulator (7). Additionally, ethanolamine activates the expression of qse 
(sensor kinase), stx2A (shiga toxin) and multiple fimbriae operons (6, 8).  The 
signalling phenotype observed here can occur in the presence of micromolar 
concentration of ethanolamine that do not activate the eut operon. It has 
therefore been proposed by Kendall et al. that there is a secondary sensor 
activated in response to micromolar concentrations of ethanolamine (6).  
More recently, the ethanolamine metabolism has been identified in UTIs. 
Human metabolome studies have measured ethanolamine in the urine of 
small numbers of healthy volunteers at concentration between 0.38 and 
0.47mM (47). RNA-seq analysis has detected expression of the eut operon in 
vivo in urine from patients with UTI (17, 46). One study found that the eut 
operon is upregulated in vivo compared to in vitro growth in sterile urine, 
suggesting host factors influence the upregulation of the operon (17). In the 
same study wild type UPEC had a colonisation advantage over their eut 
mutant in a mouse UTI infection model. More recently the expression of the 
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eut operon has been shown to assist UPEC by subverting the innate immune 
response in the bladder in a mouse models(10). eut mutants had a 
colonisation reduction in wild type UTI mouse model, while there was no 
difference in colonisation in immunocompromised mice, however the 
mechanism unknown. This new research suggests that the eut operon 
promotes fitness of UPEC during UTIs. 
  
1.6 Objectives of this Study 
The overall objective of this work is to investigate the role of ethanolamine 
utilisation in urinary tract infection. While there is evidence to suggest that 
ethanolamine contributes to pathogenesis in the gut, a link between 
ethanolamine utilisation and urinary tract infections has only begun to be 
investigated. It is hypothesised that ethanolamine utilisation by UPEC 
enhances pathogenicity by providing a competitive growth advantage in the 
nutritionally limited environment of the urinary tract, and that ethanolamine 
sensing regulates key virulence factors in UTI. This thesis will address this 
hypothesis by: 
1. Characterising UPEC in infected urine to assess whether they display 
evidence of eut operon induction or biochemical evidence of 
ethanolamine utilisation.  
2. Investigating the ability of clinical UPEC isolates to metabolise 
ethanolamine in an in vitro urine model. 
3. Investigating whether ethanolamine regulates virulence factors in 
UPEC as has been seen in EHECs.  
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Chapter 2  Materials and Methods
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2.1 Human Urine Collection and Clinical Sample Culture 
Human urines were selected from samples sent for culture at the Cork 
University Hospital (CUH), Department of Microbiology, in 7 collections over 
a 2-year period. Urines were collected on the same day as arrival at CUH 
microbiology laboratory and selected for raised white count and bacteria as 
determined by routine microscopy analysis. Clear urines with no visible white 
cells were collected as controls. The protocol was approved by the Clinical 
Research Ethics Committee of the Cork Teaching Hospitals ref ECM 4 (c) 
12/08/14.   
Urines were transported to University College Cork (UCC) before further 
analysis. On arrival at UCC 200µl of urine were centrifuged by cytospin onto 
a microscope slide. The cells were then fixed and stained using Shandon 
Kwik-Diff stain following manufacturer instructions (Thermofisher). Cells were 
centrifuged out of urine by differential centrifugation. First urines were 
centrifuged at 800xg for 10mins, before the supernatant underwent a second 
centrifugation at 4000xg for 10mins to harvest bacteria cells. The cell pellets 
were resuspended in RNA Lysis buffer (Zymo Research) and stored at -80°C 
until RNA extraction. The resulting urine supernatant was filtered at 0.2µm to 
remove any remaining bacteria and stored at -80°C until use.  
Bacteria were isolated from urine by CUH diagnostic laboratory staff using 
routine culture on CLED media. Pure colonies cultured on Columbia blood 
agar were identified by MALDI-TOF using a Microflex LT mass spectrometer 
(Bruker Daltonik) and the MALDI Biotyper software package (version 3.0). 
Antimicrobial sensitivity was determined by the VITEK® 2.0 system 
(Biomérieux) using EUCAST breakpoints. Bacterial strains were transported 
to UCC on agar slopes and stored at -80°C using cryobeads 
(FisherScientific). 
2.2 Human Cytokine detection 
Filtered urine collected from CUH were analysed for cytokines quantification 
using Meso Scale Discovery (MSD) V-PLEX proinflammatory panel I and 
Cytokine Panel II (MSD, Rockville, MD) enzyme-linked immunosorbent 
assays (ELISAs). These assays were to quantify the following cytokines: 
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interferon γ (IFN-γ), interleukin (IL) 10, IL-13, IL-1β, IL-4, IL6, IL-8, IL-5, 
IL17A and tumour necrosis factor-α (TNF-α). Assays were performed 
following manufacturer’s instructions and measured using MESO QuickPlex 
SQ120. Calibrator’s samples were run in duplicate in parallel to the urines 
and used to form a standard curve. The concentration of cytokines in the 
urine were extrapolated from the standard curve. Values which fell below the 
limits of detection were excluded from statistical analysis.  
2.3 Genome Sequencing 
DNA was extracted from UPEC isolated from infected urine. DNA was 
extracted using DNeasy Blood and Tissue Kit (Qiagen) using manufacturer’s 
instructions. RNA was removed from the samples by incubation of sample 
with 20µl RNaseA treatment for 2mins at room temperature (Sigma-Aldrich). 
Sequencing of the DNA was performed by MicrobesNG (Birmingham, UK) as 
follows. DNA libraries were prepared using Nextera XT Library Prep Kit 
(Illumina, San Diego, USA) following the manufacturer’s protocol. The 
following modification were made: DNA quantity was increase from 1ng to 2 
ng and PCR elongation time was increase from 30s to 1 min. The library 
preparation was carried out on a Hamilton Microlab STAR automated liquid 
handling system. Prepared libraries were sequenced on the Illumina HiSeq 
using a 250bp paired end protocol. 
2.4 Bioinformatics 
Sequenced reads from UPEC DNA were further analysed by MicrobeNG 
(Birmingham, UK). The reads were trimmed using Trimmomatic 0.30 with a 
sliding window quality cut off of Q15 (176), were assembled using SPAdes 
version 3.7 (177), and contigs were annotated using Prokka 1.11 (178). 
Bioinformatics analysis on assembled reads was carried out with the help of 
Professor Michael B. Prentice. Phylogenetic trees were generated from 
contig sequences with Parsnp (Harvest tool suite (179)) and edited with 
interactive tree of life(180). Parsnp produces a core genome alignment and 
identifies SNPs for tree generation by FastTrees (181). Alignment with 32 
reference genomes known to be representative of six E. coli phylogroups 
was used for phylogroup assignment (182). Gene presence in genomes was 
taken as >75% identity in BLASTN search over the full reference gene. 
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2.5 Bacterial Strains and Growth Conditions   
A list of the bacteria used in this study can be found in Table 1. Bacteria were 
routinely grown aerobically in LB broth (Table 2.2), Modified minimal media 
(Table 2.3), and Artificial Urine Medium (Table 2.4). For solid media LB broth 
was supplemented with 1.5% Bacteriological Agar (Merck Millipore). Where 
appropriate antibiotics were added to media at the following concentrations: 
Ampicillin (Amp) 100µg ml-1; Chloramphenicol (Cm) 20µg ml-1; Kanamycin 
(Km) 50µg ml-1. Ethanolamine hydrochloride (Sigma-Aldrich) was added at 
concentration specified in the text. Vitamin B12 (Sigma-Aldrich) was added to 
a final concentration of 200nM when ethanolamine hydrochloride (Sigma-
Aldrich) was added to media.  
Experiments were routinely set up by inoculating 5ml LB (plus antibiotic were 
appropriate) with 1 colony and incubated overnight at 30°C. Following 
incubation bacteria were washed in 1xPBS by centrifugation at 4000xg for 
10mins. Growth media was then inoculated to a starting OD600nm of 0.05. 
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Table 2.1. Strains used in this study.  
Name Description Source 
E. coli JW2430-1 F-, Δ(araD-araB)567, ΔlacZ4787(::rrnB-
3), λ-, ΔeutR766::kan, rph-1, Δ(rhaD-
rhaB)568, hsdR514 
KEIO Library (183)  
E. coli JW2434-1 F-, Δ(araD-araB)567, ΔlacZ4787(::rrnB-
3), λ-, ΔeutB770::kan, rph-1, Δ(rhaD-
rhaB)568, hsdR514 
KEIO Library (183)  
E. coli JW2439-1 F-, Δ(araD-araB)567, ΔlacZ4787(::rrnB-
3), λ-, ΔeutE775::kan, rph-1, Δ(rhaD-
rhaB)568, hsdR514 
KEIO Library (183) 
UPEC U1 Clinical cystitis isolate CUH, Ireland 
UPEC U2 Clinical cystitis isolate CUH, Ireland 
UPEC U3 Clinical cystitis isolate CUH, Ireland 
UPEC U4 Clinical cystitis isolate CUH, Ireland 
UPEC U5 Clinical cystitis isolate CUH, Ireland 
UPEC U6 Clinical cystitis isolate CUH, Ireland 
UPEC U7 Clinical cystitis isolate CUH, Ireland 
UPEC U8 Clinical cystitis isolate CUH, Ireland 
UPEC U9 Clinical cystitis isolate CUH, Ireland 
UPEC U10 Clinical cystitis isolate CUH, Ireland 
UPEC U11 Clinical cystitis isolate CUH, Ireland 
UPEC U12 Clinical cystitis isolate CUH, Ireland 
UPEC U13 Clinical cystitis isolate CUH, Ireland 
UPEC U14 Clinical cystitis isolate CUH, Ireland 
UPEC U15 Clinical cystitis isolate CUH, Ireland 
UPEC U16 Clinical cystitis isolate CUH, Ireland 
UPEC U17 Clinical cystitis isolate CUH, Ireland 
UPEC U18 Clinical cystitis isolate CUH, Ireland 
UPEC U19 Clinical cystitis isolate CUH, Ireland 
UPEC U20 Clinical cystitis isolate CUH, Ireland 
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UPEC U21 Clinical cystitis isolate CUH, Ireland 
UPEC U22 Clinical cystitis isolate CUH, Ireland 
UPEC U23 Clinical cystitis isolate CUH, Ireland 
UPEC U24 Clinical cystitis isolate CUH, Ireland 
UPEC U25 Clinical cystitis isolate CUH, Ireland 
UPEC U26 Clinical cystitis isolate CUH, Ireland 
UPEC U27 Clinical cystitis isolate CUH, Ireland 
UPEC U28 Clinical cystitis isolate CUH, Ireland 
UPEC U29 Clinical cystitis isolate CUH, Ireland 
UPEC U30 Clinical cystitis isolate CUH, Ireland 
UPEC U31 Clinical cystitis isolate CUH, Ireland 
UPEC U32 Clinical cystitis isolate CUH, Ireland 
UPEC U33 Clinical cystitis isolate CUH, Ireland 
UPEC U34 Clinical cystitis isolate CUH, Ireland 
UPEC U35 Clinical cystitis isolate CUH, Ireland 
UPEC U36 Clinical cystitis isolate CUH, Ireland 
UPEC U37 Clinical cystitis isolate CUH, Ireland 
UPEC U38 Clinical cystitis isolate CUH, Ireland 
UPEC U57 Clinical cystitis isolate CUH, Ireland 
UPEC U58 Clinical cystitis isolate CUH, Ireland 
UPEC U61 Clinical cystitis isolate CUH, Ireland 
UPEC U66 Clinical cystitis isolate CUH, Ireland 
UPEC U67 Clinical cystitis isolate CUH, Ireland 
UPEC U68 Clinical cystitis isolate CUH, Ireland 
UPEC U69 Clinical cystitis isolate CUH, Ireland 
UPEC U71 Clinical cystitis isolate CUH, Ireland 
UPEC U74 Clinical cystitis isolate CUH, Ireland 
UPEC U76 Clinical cystitis isolate CUH, Ireland 
UPEC U79 Clinical cystitis isolate CUH, Ireland 
U1ΔeutR::Km P1:JW2430-1→UPEC U1 This thesis  
U1ΔeutB::Km P1:JW2434-1→UPEC U1 This thesis  
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U1ΔeutE::Km P1:JW2439-1→UPEC U1 This thesis  
MG1655 K12:  F- λ- ilvG- rfb-50 rph-1 Lab stock 
HM605  Clinical Isolate from colonic mucosal 
biopsy  
Dr Barry Campbell 
(184) 
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Table 2. 2 LB Broth Recipe 
 Concentration 
Peptone  10gL-1 
Yeast extract 5gL-1 
Sodium Chloride 5gL-1 
 
Table 2. 3 Modified M9 Salts Recipe (3). Media was filter sterilised (0.2µM). 
 Concentration 
Potassium dihydrogen phosphate 22mM 
Disodium phosphate 48mM 
Sodium Chloride 8.5mM 
Calcium Chloride 0.6mM 
Magnesium Sulphate 1mM 
Thiamine (vitamin B1) 0.03mM 
Trace Metals (0.1µM ZnSO4; 0.045µM FeSO4; 
0.2µM Na2Se2O3; 0.2µM Na2MoO4; 2µM MnSO4; 
0.1µM CuSO4; 3µM CoCl2; 0.1µM NiSO4) 
2ml L-1 
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Table 2. 4 Artificial urine medium recipe (AUM) (185). pH was adjusted to 6.5. 
Media was filter sterilised (0.2µM). 
 Concentration  
Peptone from Casein  1g L-1 
Yeast extract 0.005g L-1 
Lactic acid 1.1mM 
Citric acid 2mM 
Sodium bicarbonate 25mM 
Urea 170mM 
Uric acid 0.4mM 
Creatinine 7mM 
Calcium chloride.2H20 2.5mM 
Sodium chloride 90mM 
Iron II sulphate.7H2O 0.005mM 
Magnesium sulphate.7H2O 2mM 
Sodium sulphate. 10H2O 10mM 
Potassium dihydrogen phosphate 7mM 
Di-potassium hydrogen phosphate 7mM 
Ammonium chloride 25mM 
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2.6 Screening for Ethanolamine utilisation 
2.6.1 Automated 
UPEC were screened for their ability to utilise ethanolamine as a nitrogen or 
carbon source in a modified minimal media previously used by Bertin et al. 
2011 (3). To determine utilisation of ethanolamine as a sole nitrogen source, 
ethanolamine hydrochloride (concentration specified in text) (Sigma-Aldrich) 
and 20mM glycerol (Sigma-Aldrich) was added to modified M9 media (Table 
2.3). To determine utilisation of ethanolamine as a sole carbon source, 
ethanolamine hydrochloride (concentration specified in text) (Sigma-Aldrich) 
and 20mM ammonia chloride (Sigma-Aldrich) was added to modify M9 media 
(Table 2.3). 96 well plates were filled with 200µl of culture grown in triplicate. 
The plate was incubated at 37°C using an ION Biotek plate read and OD600nm 
readings were measured using an ION plate reader over a 36-48hour period. 
Growth curves were analysed by GrowthRates (Bellingham Research 
Institute) to determine MaxOD (186).  
2.6.2 Manual 
UPEC were grown aerobically in 35mls of Modified Minimal Media 
(ethanolamine as nitrogen source) or AUM at 37°C to measure growth. 
OD600nm reading were taken ever 2-4 hours and growth was measured over 
32hours. When CFU was measured culture were diluted 10-fold and spotted 
onto LB agar (with appropriate antibiotics). Plates were incubated at 37°C 
and CFU ml-1 was calculated. During growth samples were collected for 
HPLC (Section 2.9) and gene expression analysis (Section 2.10). 
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2.7 P1 Transduction 
Knock out mutantiond in the eut operon were introduced into UPEC strain U1 
using the generalised P1 transduction method described in (187). The 
method utilises P1cml bacteriophage and bacterial strains JW2430-1, 
JW2434-1 and JW2439-1 from the KEIO library (183) as donor strain for 
gene deletion.  
2.7.1 Prepare the lysogen 
50µl of P1cml lysate (induced from E. coli ZK2686) was incubated with a 
colony of the donor strain suspended in 50µl LB (JW2430-1, JW2434-1 or 
JW2439-1) and 5µl of 1M CaCl2. The mixture was incubated statically at 
30°C for 30mins. The entire mixture was plated onto Km and Cm LB agar to 
select for the lysogen and incubated at 37°C.  
2.7.2 Preparing the lysate 
Lysate was prepared from a lysogen colony with desired knockout genotype. 
2ml of LB broth was inoculated with one lysogen colony and incubated 
overnight at 30°C. The next day the culture was used to inoculate 5ml of LB 
broth to give a starting OD600nm of 0.02 and grown shaking at 30°C until 
OD600nm=0.1-0.2. The culture was heat shocked at 42°C for 20mins shaking 
at 180rpm. The culture was moved to 37°C incubator until total lysis was 
observed. Chloroform (final concentration 2% v/v) was added to the lysate 
and vortexed before the mixture was centrifuged to remove cell debris. The 
lysate was filter sterilised using a 0.2µm filter and stored at 4°C until used.  
2.7.3 Transduction  
Overnight culture were prepared as described (Section 2.5) and incubated at 
37°C. The next day the cells were pelleted by centrifugation at 4000xg for 
10mins and suspended in 5ml Transduction Buffer (10mM MgSO4, 5mM 
CaCl2). A mixture of 100µl of U1 suspended in Transduction Buffer and either 
10µl, 100µl or 200µl lysate were incubated at 37°C for 30mins. A cell free 
and a lysate free control were set up in parallel. After this incubation 200 µl of 
1M sodium citrate was added to the mixture and incubated for a further hour 
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at 37°C. The cells were pelleted in 1.5ml Eppendorf tubes by centrifugation 
at 12,000 x g in a microcentrifuge and the supernatant was removed. The 
cells were then washed in 100µl LB broth with 20mM sodium citrate before 
suspension in 100µl LB broth with 20mM sodium citrate. The mixture was 
spread plated onto Km LB agar containing 20mM sodium citrate and 
incubated at 37°C overnight. Colonies were purified by restreaking onto Km 
LB agar with 20mM sodium citrate. Insertion of the Kanamycin cassette was 
confirmed by colony PCR (Section 2.7.4) and whole genome sequencing 
(MicrobesNG, Birmingham, UK) (Section 2.3). 
2.7.4 Colony PCR 
Colony PCR were used to confirm successful transduction of UPEC strains.  
Single colonies were suspended in 50µl molecular grade H2O and 0.5µl of 
suspended colony was used as the DNA template in a 25µl PCR reaction. A 
colony of corresponding KEIO strain and a colony of wild type strains were 
used as positive and negative controls respectively along with H2O.  Each 
PCR reaction contained 5µl 5XGreen GoTaq® reaction buffer (Promega), 
0.5µl 10mM dNTPs(NEB), 1 µl 20mM Primer 1, 1 µl 20mM Primer 2, 0.125µl 
GoTaq G2 DNA polymerase (Promega), 0.5µl DNA template and H2O 
molecular grade up to 25µl. PCR conditions were as followed: 95°C for 
5mins; 30 cycles of (95°C  for 30s, primer specific annealing temperature for 
30s, 72°C for 1mins per kb);75°C for 5mins. 5µl of the resulting PCR product 
were run on a 1% agarose gel to determine successful transformation.  
Primers used for colony PCR are listed in Table 2.5. 
2.7.5 DNA gel electrophoresis 
DNA electrophoresis was carried out on a 1% (w/v) agarose gel in 1x Tris-
Acetate-Ethylenediaminetetraacetic acid (EDTA) buffer. Ethidium bromide 
(Sigma-Aldrich) was added to the gel to achieve a final concentration of 
0.5mg ml-1. Where loading dye (NEB) was needed it was added to a final 
concentration of 1X. Quick-Load purple 1kb DNA ladder (NZY Tech) was 
added to each gel. Gels were electrophoresed at 100V for 30mins and DNA 
bands were viewed under UV light.  
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Name Sequence 5'-3' Source 
KD13_K1 CAGTCATAGCCGAATAGCCT Baba et al. (183) 
KD13_K2 CGGTGCCCTGAATGAACTGC Baba et al. (183) 
eutR_L TTGTTGGCGCTGTTAACATC This study 
eutR_R GGCGGGCTGTTCTTTGATGA This study 
eutB_L3 TACCCTTTCGCTCTCTGGCAG This study  
eutB_R3 AGTGATCGGCCAGGAAACGCA This study 
eutE_L 
ATTGTCGATGAGGTGGTGTC 
This study 
eutE_R TGGTTACACAGCGTTGCC This study 
eutRin_L TCGTTCTGGTTTGGCATTCC This study 
eutRin_R 
GACGGCTTCTCGGAAAACAG 
This study 
eutBin_L 
ATGTGCTGAGCGATGAAACC 
This study 
eutBin_R CCCATGATGTAGTTGCAGCC This study 
eutEin_L ATTGCTGCCATTCGTGAAGC This study 
eutEin_R ATGTTCTGCGGTGGTTTCCA This study 
cpz_pl65_R CGGGCAATGTGATTGTTG This study 
Table 2.5 Primers used for colony PCR. Primers were designed using Primer3 
and synthesised by Sigma-Aldrich. 
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2.8 Complementation of knockout mutants 
The ASKA E. coli library is a complete set of cloned individual genes (188). 
The genes are cloned into the plasmid pCA24N and is under the control of 
the PT5- lac promotor. Introducing the plasmids into the knock out mutants 
allows for the expression of the deleted gene in the presence of Isopropyl β-
D-1-thiogalactopyranoside (IPTG).  
2.8.1 Plasmid extraction 
Plasmids were extracted from the ASKA E. coli library of ORF clones. The 
plasmids were extracted from the donor cell using the GeneJet Plasmid 
MiniPrep kit (Thermo Scientific) following manufacturer’s instructions. To 
confirm the plasmid extraction, 5µl of plasmid DNA was run on a 1% (w/v) 
agarose gel.  
2.8.2 Preparing electrocompetent cells 
Overnight cultures were diluted 1:500 in 100ml LB broth and incubated at 
37°C until OD600nm reached 0.4-0.7. Cells were pelleted by centrifuged at 
4000xg for 10mins at 4°C. The supernatant was removed, and the bacterial 
pellet was suspended in 100ml of ice cold sterile MilliQ water. Bacteria were 
pelleted as above, and the pellet was suspended in 50mls ice cold sterile 
MilliQ water. The bacteria were pelleted as above, and cells were in 
suspended in 1.6ml ice cold 20% (v/v) glycerol. Bacteria were pelleted for a 
final time before the resulting pelleted was suspended in 150µl of ice cold 
20% (v/v) glycerol. The bacterial suspensions were stored in 50µl aliquots at 
-80°C until required.  
2.8.3 Electroporation 
Each mutant was complemented by the electroporation of the strain with 
pCA24N and either pCA24N::eutB, pCA24N::eutE or pCA24N::eutR. 
Electrocompetent cells and plasmids were defrosted on ice and 2µl of 
plasmid was added to the 50µl of competent cells. The mixture was 
transferred to a 2mm electro cuvette and pulsed on setting Ec2 (2.5kV) of 
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BioRad micro-pulsar. Immediately after electroporation 950µl of pre-warmed 
LB was added to the cells and the culture was incubated shaking at 37°C to 
recover for 1-2hrs. The culture was then plated on LB plates containing 
appropriate antibiotics. Colony PCR confirmed the presence of the plasmid.    
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2.9 High Performance Liquid Chromatography 
High performance liquid chromatography (HPLC) was used for the detection 
and measurement of metabolites in urine and bacterial media supernatant. 
Media was removed from cultures (2.6.2) and filter sterilised through a 0.2µm 
syringe top filter. Samples were frozen at -80°C until used.  
2.9.1 Ethanolamine detection 
Ethanolamine was measured by gradient HPLC using an Agilent 1250 Infinity 
HPLC system after derivatisation with o-phthaldialdehyde (OPA) using a 
method adapted from Sturms et al. (189).  The mobile phase consisted of 
Buffer A [10% methanol (Sigma-Aldrich) -90% 10mM Na3PO4 (pH7.3) 
(Sigma-Aldrich)], and Buffer B [80% Methanol- 20% 10mM Na3PO4 (pH7.3)]. 
Samples were prepared using an in-loop derivatization reaction where 6µl of 
sample were taken up followed by 6µl 10mg/ml OPA and 3-
mercaptopropionic acid in 0.4M boric acid (Agilent Technologies) and 
incubated at room temperature for 3 minutes. The samples were injected into 
a 4.6 by 100mm, 2.7µm pore Infinity Lab Poroshell HPH-C18 column (Agilent 
Technologies) and eluted with 5ml linear gradient from 50% Buffer B to 100% 
Buffer B followed by 5mls of 100% Buffer B at as constant flow rate of 1ml 
min-1. The excitation was detected at 224nm. A standard curve was created 
before each sequence run. Identification of the peak and quantification was 
determined by comparison to retention time and standard curve.  
2.9.2 Acetate and ethanol detection  
Acetate and ethanol were measured by HPLC using an Agilent 1200HPLC 
system with a refractive index detector. 10µl of sample was injected into a 
REZEX 8µm 8%H, Organic Acid Column 300x7.8mM (Phenomenex, USA) 
and eluted with 15ml of 0.01M H2SO4 at a flow rate of 0.6ml min-1. The 
column was maintained at 65°C for the duration of the experiments. 
Substrate identification was determined by comparison of retention time to 
pure compound and concentrations were quantified by comparison to known 
standards.  
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2.10 Gene expression  
2.10.1 RNA extraction and DNase digestion  
Bacteria cultures from experimentation in section 2.6.2 were collected from 
media at specific time points by centrifugation at 4000xg for 10mins at 4°C. 
Bacteria were suspended in 1ml RNALater (ThermoScientific) and incubate 
at 4°C overnight. Bacteria were pelleted from the solution by centrifugation 
as above, and the supernatant removed. Bacterial pellets were stored at -
80°C until RNA was extracted.  
RNA was extracted from bacterial pellets using the Zymo Fungal/Bacterial 
Mini Prep kit following manufacturer’s instructions.  On column DNAse was 
performed using Zymo DNase treatment. After extraction, if residual genomic 
DNA was detected by PCR of adk, samples were treated with TURBO DNA-
free (Ambion) DNAse I treatment. The RNA was quantified using the 
Nanodrop 1000 spectrophotometer.  
2.10.2 cDNA synthesis 
cDNA was synthesised by reverse transcription carried out in nuclease free 
96well plates. RNA was diluted using molecular grade H2O (Sigma-Aldrich) 
to a final concentration from of 100ng µl-1 in a 10µl volume. The RNA was 
mixed with: cDNA reaction was set up 4ul 5x Reverse transcription Buffer 
(Roche); 3ul Random Hexamer Primer (Roche); 2ul 20mM dNTPs mix; and 
1ul Reverse transcriptase/RNase Inhibitor to give a total volume of 20µl. The 
reaction mixture was incubated in a thermocycler in the following condition: 
10mins at 25°C; 30mins 55°C; 5mins at 85°C; hold at 4°C. The cDNA was 
then diluted to 100µl and stored at -20°C until use. 
2.10.3 Quantitative Polymerase Chain Reaction (qPCR)  
The Universal Probe Library (Roche- based on Primer3) was utilised to 
design primers for quantitative PCR. The primers designed and used in this 
study are listed in Table 2.6. Amplification reactions were a mix of: 3µl of 
cDNA; 7µl TaqMan Probe Master Buffer (Roche); 1µl 20mM primer mix (L+R 
primers); 0.1µl of 10mM probe (Roche); and 0.9 µl molecular grade H2O to a 
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make a final volume of 10 µl. When the probe was not available a SYBR 
Green master mix was used which included: 3 µl cDNA, 5 µl 2xSYBR Green I 
Master buffer (Roche); 1µl 20mM primer mix (L+R primers) and 1µl molecular 
grade H2O to a final volume of 10 µl.  All reactions were performed using a 
384 well plate on the LightCycler®480 System (Roche) with Molecular grade 
water included as a negative control. Thermal cycling condition were as 
follows: 50°C for 2mins, 95°C for 10 mins followed by 45 cycles for 95°C for 
10s, 60°C for 45 and 72°C for 1.  Relative gene expression was calculate 
using the 2-ΔΔCt (190). Fold changes in mRNA of target gene was quantified 
relative to the geometric mean of the housekeeper genes gyrA and rrsB for 
bacteria gene expression.   
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Name Sequence 5'-3'  
EC_gyrA_L GCAGGATCGCAGTGATAGC This study 
EC_gyrA_R GTCGTCCGATCGTCAACC This study 
EC_rrsA_pL5_L GACGATCCCTAGCTGGTCTG This study 
EC_rrsA_pL5_R CGTAGGAGTCTGGACCGTGT This study 
EC_eutB_pL_34_L  CGCGGAGTTCAACCGTAT This study 
EC_eutB_pL_34_R  CAGAGCCTTGTCCGGTTTC This study 
EC_eutR_pL_74_L TGTCTATGAACATGCTTTAACGATT This study 
EC_eutR_pL_74_R CGGATGCAGCTGATCGTA This study 
EC_eutS_pL_153_L CACACTGGCGCATCTCAT This study 
EC_eutS_pL_153_R CCGGGAGTTAGCGTCATAAT This study 
EC_fimH_pL_68_FL ATTGATGCGGGTCATACCA This study 
EC_fimH_pL_68_R ACGTTTGTTGCGCTACCC This study 
EC_fimE_pL40_L  TGACCGGACTGACGCTATATTT This study 
EC_fimE_pL40_R ATACCGGCATCGCGAATA This study 
EC_fliC_pL28_L CGGTAACCTGACGAAAAACC This study 
EC_fliC_pL28_R CCGTTGAAAATACCGTCCAA This study 
EC_flhD_pL67_L CAAGATTCCCGCGTTGAC This study 
EC_flhD_pL67_R GCAAGCGTGTTGAGACAT This study 
 
Table 2.5 qPCR Primers used in this study. Primers synthesised by Sigma Aldrich.  
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2.11 Competition Assay  
The Competitive Index of wild type strains compared to mutants was 
investigated as previously described (3). Wild type and deletion mutant 
cultures were prepared up by inoculating 5mls of LB broth with a single 
colony of bacteria and incubated overnight at 30°C. The following day the 
bacteria were pelleted by centrifugation at 4000xg for 10mins and washed in 
1xPBS. Artificial urine media was inoculated with approximately equal 
concentrations of wild type and mutant bacteria to a starting OD600nm=0.1. 
Parallel culture were set up with 0mM, 0.5mM or 10mM ethanolamine and 
200nM B12 added. The bacterial cultures were incubated at 37°C with 
shaking. After 24 hours growth the OD600nm was measured and bacteria were 
inoculated into fresh AUM with corresponding concentration of ethanolamine 
to give a starting OD600nm of 0.05. These cultures were incubated at 37°C 
with shaking. At each time point co-cultures were serially diluted 10-fold and 
spotted onto LB and LB Km agar. Agar plates were incubated at overnight 
37°C. The CFU ml-1 of the mutant strains was calculated from the Km 
selective agar and the CFU ml-1 of the wild type bacteria was calculated by 
subtracting the CFU ml-1 of mutant bacteria from the CFU ml-1 of bacteria 
grown on the LB agar. These values were used in the following equation to 
determine the competitive index at each time point:  
 
A competitive index below 1 indicates that the wild type was outcompeting 
the mutant strain at that time point. The CI at time zero is by definition 1.  
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2.12 Transmission Electron Microscopy 
Bacteria pellets were prepared for sectioning and imaging by transmission 
electron microscopy. After growth in AUM with or without 10mM 
ethanolamine, bacteria cells were pelleted by centrifugation for 10 mins at 
4,000xg, to give a pellet no larger than 500µl in volume. The supernatant was 
removed, and the cells were incubated in 2ml of 2.5% glutaraldehyde 
(Flukka) diluted in 0.1M Sodium cacodylate pH 6.8 (CAB) (bioWORLD). After 
incubation overnight at 4°C, the bacteria were pelleted by centrifugation as 
above and the pellet was suspended in 2ml of 2.5% glutaraldehyde diluted in 
CAB before being sent to University of Kent, Canterbury, UK for embedding, 
sectioning and imaging by Dr Mingzhi Liang.  
The bacteria were stained for 1 hour in 1 ml of 1% osmium tetroxide (w/v) 
(250µl 4% osmium tetroxide; 250 µl MiliQ H2O; 500 µl CAB). The pellets 
were washing in 2ml MiliQ H2O for 10 minutes twice before the pellets were 
dehydrated. Pellets were dehydrated through an ethanol (EtOH) gradient as 
follows: 50% EtOH (v/v) x 10mins; 70% EtOH x 10min; 90% EtOH x 10mins; 
100% EtOH x 10mins three times and then the bacterial pellets were washed 
twice in propylene oxide for 10mins. The pellets were embedded into 
resuspended in 1.5% ml propylene oxide: LV resin at 1:1 for 30 min followed 
by incubation 2 × 1.5 h in 100% freshly made agar LV resin. The pellets were 
resuspended in 1ml of 100% LV resin and transferred to a conical bottom 
flask. The bacterial pellet was centrifuged at 900xg for 5mins and was left to 
incubate at 60°C for 24hours.  
Bacteria were sectioned to 65nm with a diamond knife on a MT‐6000‐XL 
ultramicrotome. Sections were collected on 400 mesh copper grids and 
stained with 4.5% (w/v) uranyl acetate in 1% acetic acid (v/v) for 45mins and 
Reynolds lead citrate for 7mins at room temperature. Sections were then 
observed on a Jeol 1230 transmission electron microscope operated at an 
accelerating voltage of 80kV and imaged with a Gatan MultiScan 791 digital 
camera.  
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2.13 Haemagglutination  
Haemagglutination assay were performed as previously described (38, 191, 
192). 5mls of LB was inoculated with a single colony of bacteria were grown 
statically at 37°C overnight. The next day the bacteria were normalised to 
OD600nm=1 and 1ml of culture was centrifuged at 8000xg for 3 mins. The 
pellet was suspended in 1xPBS (Sigma-Aldrich) or 4% mannose (Sigma-
Aldrich) in PBS and incubated at room temperature for 10mins. The 
suspensions was diluted 2-fold in 96-well round bottom plates using PBS 
until 2-6 dilution with control wells of PBS and 4% mannose. Guinea Pig 
Erythrocytes (TCS Bioscience) were prepared by washing in PBS before 
making a 5% solution in PBS. Equal volume of the erythrocyte suspension 
was added to each well and the plates were left to incubate overnight at 4°C. 
Haemagglutination titre was determined by recording the maximum dilution 
before the formation of an erythrocyte button.  
2.14 Yeast Agglutination  
Bacterial culture prepared for haemagglutination assay in section 1.16 were 
tested for type 1 fimbriae production using yeast agglutinations. A 0.5% 
baker yeast Saccharomyces cerevisiae solution was made up and 25µl of 
culture was mixed with 25ul of yeast solution in a flat bottom 96 well plate. 
The mixture was incubated shaking for 10mins at room temperature before 
agglutination was determined. Agglutination was measured as + or -.  
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2.15 Cell Culture. 
The human bladder cell carcinoma cell line HT1376 (ATCC CRL-1472) was 
maintained in High Glucose Dulbecco Modified Eagle Media (DMEM)(Sigma-
Aldrich) supplement with 10% Foetal Bovine serum (FBS) (Gibco), 200mM L-
Glutamine (Sigma-Aldrich) and 100U ampicillin, 100µg streptomycin ml-1 
(Sigma-Aldrich). When the cells reached 90% confluency the cells were 
passaged using 0.25% trypsin-EDTA (Sigma-Aldrich).The cells were 
maintained in a cell incubator at 37°C and in 5% CO2. All work involving 
epithelial cells were carried out in a Class II Laminar Flow cabinet.  
2.15.1 Epithelial cell Co-culture.  
Cells were seeded into 24 well-plates in DMEM supplemented with 10% 
Foetal Bovine Serum (Gibco) and 200mM L-Glutamine (Sigma-Aldrich) and 
grown until 90% confluency achieved. On the day of infection, cells in the 
control wells were counted using 0.4% Trypan Blue (Sigma-Aldrich) and used 
to determine the Multiplicity of Infection (MOI) 1:10.  Overnight bacterial 
cultures were washed 2x in PBS and OD600nm reading were used to estimate 
CFU (OD600nm 1=7.5x108 CFU ml-1). Low-glucose DMEM (Sigma-Aldrich) 
supplemented with 10% FSB was inoculated with bacteria to obtain a MOI of 
10 and where appropriate was supplemented with 10mM Ethanolamine-
Hydrochloride (Sigma-Aldrich) and 200nM B12. Cells were washed with PBS 
before 1ml of the inoculated bacteria was added to the cells. The cells were 
inoculated in triplicate. 
2.15.2 Bacterial invasion assay 
The bacteria and epithelial cells were incubated for 4hrs before the 
supernatant was removed and the cells were washed 3x with PBS. The cells 
were then incubated for a further hour with 50µg ml-1 Gentamicin (Sigma-
Aldrich) before cells were washed 3x in PBS and lysed in 300µl 0.1% Triton 
X-100. All the lysate was plated onto 3 LB plates and incubated at 37°C 
overnight. Colonies were counted and the total CFU of invasive bacteria was 
calculated.  
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2.15.3 Adherence assay   
The bacteria and epithelial cells were incubated for 3hrs. After this time the 
supernatant was collected, and the cells were washed 3x in PBS. The cells 
were lysed in 100µl 0.1% Triton X-100 and diluted 10-fold in PBS. Dilutions 
were spotted (20 µl) on to the LB agar in triplicate and the plates were 
incubated at 37°C overnight. The following day colonies were counted and 
CFU ml-1 was calculated.  
2.16 Statistical Analysis 
Statistical analysis was carried out using GraphPad prism 5.03 software. 
Student T-test and Mann Whitney U tests (non-parametric) was carried to 
compare two groups. A one-way ANOVA, with Tukey post-test or Kruskal 
Wallis, with Dunn’s multiple comparison (non-parametric) was used to 
compare 3 or more groups. Correlations were measured and significance 
was tested using Pearson rank or Spearman’s Rank (non-parametric). 
Significance was assumed when p≤0.05. 
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Chapter 3  Investigation into Ethanolamine 
metabolism in infected patient urines 
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3.1 Abstract 
Urinary tract infections (UTIs) are a common bacterial infection worldwide 
(18). The majority of UTIs are caused by E. coli (11). Putative virulence 
factors in the genome of uropathogenic E. coli (UPEC) has been linked to the 
colonisation of the urinary tract, however these are not conserved between 
UPEC in different studies (193). Host-mediated induction of core bacterial 
pathways however has been associated with colonisation in murine models 
(38). Transcriptome analysis has found that host induction of ethanolamine 
metabolism occurs in UPEC infection of humans and it confers a colonisation 
advantage in vivo in the mouse UTI model (17). Additionally, ethanolamine 
metabolism has been associated with bladder colonisation by subverting the 
innate immune system in the murine model (10).  
In this study, infected urines were collected from Cork University Hospital. 
Bacterial isolates from urine were identified by MALDI-TOF and the genomes 
of UPEC isolates were sequenced. UPEC genome sequences were analysed 
for the presence of virulence factors. The presence of the ethanolamine 
utilisation operon was conserved across all strains, while putative 
urovirulence factors were concentrated in phylogroup B2 strains. Gene 
expression analysis confirmed the up regulation of the eut operon in infected 
urine, and ethanolamine was present at a mean concertation of 0.57mM. 
Typical breakdown products of ethanolamine metabolism were also present 
in urine. There was no significant correlation between cytokine expression 
and ethanolamine concentration detected in the urine. In conclusion, in this 
Chapter the presence of ethanolamine was detected in infected urine and 
evidence for the upregulation of the eut operon in E. coli infected urine.  
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3.2 Introduction 
The urinary tract is a common site for bacterial infection and it is estimated 
that 150 million episodes occur globally per year (18). Urinary tract infections 
(UTIs) cause significant morbidity in women with 50% of women expected to 
experience at least one UTI in their life time (20). As a result, there is a 
significant financial burden on the healthcare system, with an estimated 
US$6 billion spent per year in treatment and management of UTIs worldwide 
(1).  
E. coli are responsible for the majority of  UTI, accounting for approximately 
75% of all UTIs diagnosed, and over 80% of uncomplicated UTIs (11). E. coli 
that cause UTIs generally reside in the gut harmlessly, however they can 
migrate to other environments such as the urinary tract and the blood-stream, 
where they cause infection (193). E. coli that cause infection outside the 
intestines are known as extra-intestinal pathogenic E. coli (ExPECs), with 
uropathogenic E. coli (UPEC) being a specific term for E. coli that cause UTI 
(193).  
UPEC cause uncomplicated UTIs by migrating from the gut to contaminate 
the periurethral area (194). This is followed by colonisation of the urethra and 
ascend into the bladder, via the urethra, where UPEC utilise adaptive 
mechanisms, or virulence factors to cause infection. The UPEC can ascend 
to the upper urinary tract and the kidney causing localised damage and in a 
small number of cases can enter the blood stream to cause bacteraemia 
(11).  
The genome of E. coli is highly variable with the size ranging from 4.3Mbp to 
5.3Mbp (195). The wide variation in E. coli genome size reflect presence of 
pathogenicity factors, with laboratory adapted K-12 E. coli having on average 
smaller genomes than pathogenic E. coli (30). ExPECs generally have the 
largest genomes, such as the prototypical UPEC CFT073 which has one of 
the largest E. coli genomes sequenced to date with 8-11% more open 
reading frames than most other E. coli strains (31). The large size of these 
genomes is due to the presence of multiple putative pathogenic genes and 
Pathogenicity Island (26). However, unlike other E. coli pathotypes, ExPECs 
lack a set of conserved genes related to pathogenesis (38). E. coli are 
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classified into phylogenetic groups (A, B1, B2,C ,D1, D2, E)  based on 
genetic similarity and different E. coli pathotypes have been found to cluster 
into similar phylogroups (196). ExPECs typically belong to B2 and the 
majority of UTIs in USA and Europe are caused by UPEC in group B2 (197, 
198). Other phylogenetic groups, A, B1, D2 account for between 25 and 50% 
of all cystitis strains (199). All commonly studies UPEC strains such as 
CFT073 and UTI89 are B2 strains, while UPEC in other phylogroups haven’t 
been studied in detail (86).  
A recent study has shown that B2 strains encode more putative urovirulence 
factors (PUFs), than other phylogenetic groups, regardless of pathotype (38). 
These PUFs include adhesins, toxins, iron accumulation system and invasins 
(193). Adhesins, such as type 1 fimbriae are crucial for initial colonisation of 
the urinary tract(91). Type 1 fimbriae however are conserved across all E. 
coli and are associated with the successful colonisation of UPEC in the 
murine bladder (91). Interestingly, adhesion via type 1 fimbriae also mediates 
the invasion of bladder epithelium to form intracellular communities, where 
bacteria can evade the host immune system (90). In addition to traditional 
virulence factors, metabolic loci have been proposed to be important for the 
colonisation of the urinary tract. D-serine, the most abundant amino acid in 
urine is preferentially used by E. coli in the urine to provide growth 
enhancement (58, 200). 
Despite the presence of various virulence factors in UPEC, murine model 
studies have failed to detect an association between the numbers of putative 
urovirulence genes present in individual strains and a pathogenic phenotype 
(38). Instead the regulation of core bacterial processes in response to 
environmental cues, such as the host environment, is more predictive of 
virulence in the murine urinary tract (38). In a separate study, the copper 
tolerance pathway (cus), and ethanolamine utilisation (eut) operon were 
upregulated in infected urine collected from patients compared to the same 
bacteria grown in urine in vitro. Mutational studies found that these host 
inducted pathways provided a competitive colonisation advantage in a mouse 
model (17).   
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Ethanolamine is found naturally in the body as part of the phospholipid 
phosphatidylethanolamine (132). Breakdown of this phospholipid from cell 
membranes releases ethanolamine that can be metabolised by bacteria 
(136). Within the gastrointestinal (GI) tract, for example the bovine intestinal 
tract, where there is high turnover of epithelium, ethanolamine is present at a 
concentration of 2.2mM and provides a competitive growth advantage for 
enterohaemorrhagic E. coli (EHEC) (3). Within the normal urinary tract 
epithelial turnover is 5-60 fold slower than the gut (up 200 days), and 
therefore in health would not provide a large source of ethanolamine (201). 
However, excretion of ethanolamine in urine has been reported in healthy 
urine (47). A characteristic of UTI is the presence of numerous inflammatory 
and bladder epithelial cells (BECs) in urine which could provide an alternative 
source of ethanolamine (202). Host recognition of bacteria in the urinary tract 
mediate the release of proinflammatory cytokines such as Interleukin (IL) 6 
and IL-8 by the epithelium recruiting masses of neutrophils to the bladder 
(106, 120). Additionally, the invasion of epithelium by E. coli mediates 
epithelial sloughing (42).  
In this study infected urines from Cork University Hospital (CUH), were 
assessed for the presence of ethanolamine, evidence of ethanolamine 
metabolism by invading bacteria, and a correlation between the host and 
inflammatory response and ethanolamine metabolism. Genomic analysis of 
E. coli isolates for phylogeny and the presence of putative virulence factors 
was also performed.  
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3.3 Results 
3.3.1 E. coli infection account for the majority of clinically infected 
urine samples collected in this study. 
It has previously been reported that E. coli accounts for approximately 75% 
of UTIs (1).  103 infected urines were collected and cultured with speciation 
of isolates at CUH Microbiology laboratory. 61 of the 103 urines collected 
were infected with E. coli, which equates to around 55% (Fig 3.1).  
 
 
 
 
 
Figure 3.1 The majority of urines were infected with E. coli. N=103 
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3.3.2 Genomic Analysis of UPECs 
The genomes of UPEC isolated from infected urines were sequenced by 
MicrobesNG using Illumina HiSeq 2500 2x250bp paired-end reads as 
described in Chapter 2. The 47 UPEC genomes were aligned with 32 
reference E. coli genomes representative of six different phylogroups using 
parsnp (Fig 3.2)(179, 182). The sequenced UPEC occupied all 6 
phylogenetic groups however the largest single group was B2 with 47% of 
the UPECs. This is followed by D2 with 23%, A with 15%, B1 with 9%, D1 
with 4% and finally E with 2%. This distribution matches observation of other 
samples of UPECs (38). 
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Figure 3.2 Phylogenetic analysis of uropathogenic E. coli strains (UPEC). Core 
genome alignment of 47 UPEC (red) with 32 reference strains representative of six E. 
coli phylogroups (black). Phylogenetic assignments shown in the vertical bar on the 
right. N=79. Professor Michael B Prentice 
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The genomes of the UPECs were analysed for the presence of 31 putative 
virulence factors (PUFs) which have previously been found to be associated 
with the UPECS compared to other E. coli strains (38).  Presence of PUF 
was determined by BLASTN. All 31 putative virulence factors were detected 
in the 47 UPECs, with a range of 2 to 25 PUFs per strain. Those UPECs that 
fall into phylogroup B2 had significantly higher PUFs than non-B2 strains (Fig 
3.3b) (p<0.001, Mann-Whitney U).  Antibiotic resistance phenotypes were 
also analysed for phylogenetic relationships. The majority (59.6%) of E. coli 
strains were resistant to one or more antibiotic, however no phylogenetic 
relationship with number of antibiotic resistances was discernible (Fig 3.3c). 
Hierarchical clustering found that strains clustered based on B2/non-B2 
phylogeny associated in relation to PUF presence but not antibiotic 
resistance genes presence (Fig 3.3a).  
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Figure 3.3 Carriage of Putative urovirulence factors (PUFs) is associated with 
phylogenetic group B2. A Heat map of presence of 31 previously described PUF (y 
axis) in UPEC. Two dimensional hierarchical clustering shows PUF co-occurrence by 
strain (upper y-axis dendrogram) and PUF association with phylogeny (x-axis 
dendrogram). UPEC highlighted in black are B2. Clade B2 strains are indicated by white 
names on a black background (x-axis labels). Lower diagram shows hierarchical 
clustering of resistance (dark grey squares) and sensitivity (pale grey squares) to nine 
different antimicrobials (lower y-axis dendrogram) by strain phylogeny. Abbreviations as 
follows: Gent, Gentamicin; Nitro, Nitrofurantoin; Cipro, Ciprofloxacin; Levo, Levofloxacin; 
Tetra, Tetracycline; Cotrim, Cotrimoxazole; PipTaz, Piperacillin/tazobactam; Amp, 
Ampicillin; Coamox , Amoxicillin/clavulanic acid. B Comparison of PUF scores between 
B2 and non-B2 UPECs. C Comparison of number of antibiotic resistances between B2 
and non-B2 UPECs. Mann-Whitney U test *** p<0.0001.  N=47 
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In addition to the putative virulence factors mentioned above, metabolism has 
been found to play a role in UPEC pathogenesis. D-serine metabolism has 
been linked to colonisation advantage in a murine model (203). The D-serine 
tolerance locus (dsdCXA) which is responsible for the breakdown of D-serine 
was present in 57% of the UPECs.  B2 strains were more likely to possess a 
complete dsdCXA locus than non-B2 strains with 77% of B2 having a 
dsdCXA locus compared to 40% in non-B2 UPECs (Table 3.1). In contrast to 
the dsd locus, the ethanolamine utilisation operon (eut) operon that controls 
the metabolism of ethanolamine in E. coli was conserved across all the 47 
UPEC strains. In one strain U71 the operon was interrupted by the presence 
the prophage insertion between eutA and eutB (Fig 3.4). This insertion site is 
also occupied by a prophage in the K12 strain MG1655 (204).  
 
Table 3.1 Frequency of D-serine tolerance locus (dsdCXA) and eut operon in UPEC 
strains based on phylogenetic group.  
 
  Frequency Percentage of all 
UPECS 
dsdCXA A 7 100.0% 
 B1 0 0.0% 
 B2 17 77.3% 
 D1 2 100.0% 
 D2 1 9.1% 
 E 0 0.0% 
 All UPECs 27 57.4% 
    
eut A 7 100.0% 
 B1 4 100.0% 
 B2 22 100.0% 
 D1 2 100.0% 
 D2 11 100.0% 
 E 1 100.0% 
 All UPECs 47 100.0% 
 
  
 
 Figure 3.4 Presence of prophage between eutA and eutB in U71. Gene of the eut operon are in blue; gene of the prophage in red. 
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3.3.3 Free ethanolamine is detectable in Urine  
To assess whether ethanolamine metabolism is important for bacteria 
colonisation and survival in the urine, collected urines were filtered and 
stored for detection of ethanolamine. HPLC was used to measure the 
concentration of ethanolamine in urine as previously described (Chapter 2) 
(189). The average concentration of free ethanolamine was measured in 64 
of the urines collected. The average concentration of ethanolamine in 
infected urine was 0.548mM while the concentration on non-infected urine 
was 0.653mM. Comparing the two groups did not show a significant 
difference in the level of ethanolamine (Fig 3.5a) (Mann-Whitney U test). 
There was likewise no significant difference detected between UPEC and 
non-UPEC infected urines when the levels of ethanolamine were compared 
(Mann-Whitney U test) (Fig 3.5b). The mean concentration of ethanolamine 
in all urines was 0.567mM.  
 
 
Figure 3.5 Ethanolamine concentration in urine is not associated with presence of 
infection. Ethanolamine concentration in urine was measured using HPLC. A. 
Concentration of ethanolamine in infected urines (n=52) vs non-infected urines (n=12). B 
Concentration of ethanolamine in E. coli infected urines (n=19) vs non-E. coli infected 
urines (n=28). Mann Whitney-U test. 
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3.3.4 Evidence for ethanolamine metabolism 
As ethanolamine was detected in the urine at an average concentration of 
0.57mM, UPECs were assessed for expression of the eut operon in urine. 
RNA was extracted from 24 bacteria pellets from infected urines, of which 18 
were identified as E. coli, and 6 were mixed cultures, with one strain being E. 
coli. The expression of the eut operon was then measured using qRT-PCR.  
To determine whether ethanolamine was sensed in the urine, expression of 
the regulator eutR was measured.  In 62.5% of the samples eutR expression 
was detected at an average 2.3-fold expression relative to gyrA (Fig 3.6a). 
Next, expression of eutB which encodes the major subunit of the 
ethanolamine ammonia-lyase enzyme which is responsible for the first stage 
of ethanolamine metabolism was measured. In 88% of the RNA samples, 
eutB was detected with an average 3.1-fold expression relative to gyrA (Fig. 
3.6). The final gene measured for relative expression was eutS, which 
encodes a protein subunit the eut bacterial microcompartment, a 
proteinaceous structure that encloses the ethanolamine metabolic pathway. 
eutS was detected in 68% of the samples with 2.4-fold expression relative to 
gyrA (Fig 3.6).  
To determine if the expression of the eut operon is linked to the 
concentration of ethanolamine in the urines, correlations between relative 
expression and ethanolamine concentration were measured. There were 
weak correlations between eutR (r=0.423) and eutS (r=0.309) expression 
compared to ethanolamine concentration (Fig 3.6) and these correlations 
were not statistically significant (Spearmans Rank). In contrast a strong 
positive correlation between expression of eutB and ethanolamine 
concentration was present (r=0.815, p<0.001, Spearmans Rank) (Fig 3.6). 
This provided evidence that infecting UPEC were actively responding to the 
concentration of ethanolamine in urine.  
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Figure 3.6 eut operon expression in detected in E.coli infected urine. A qRT-PCR of eut 
operon expression relative to gyrA. Proportion of E. coli where expression was detected B 
Correlation between relative expression of eutR and ethanolamine concentration in urine. C 
Correlation between relative expression of eutB and ethanolamine concentration in urine. D 
Correlation between relative expression of eutS and ethanolamine concentration in urine. *** 
p<0.001 n=24 
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Next, acetate concentration in urine was measured by HPLC. Acetate is a 
product of ethanolamine metabolism and the catabolism of some amino 
acids by bacteria (205, 206). As such, the level of acetate in urine has  
recently been identified as a biomarker for UTI status (207). In this study, 
acetate levels were first compared between infected urine (18.3mM) and 
non-infected urine (14.7mM), to determine if bacterial metabolism contributed 
to acetate excretion. There was no significant difference measured between 
these two groups (Mann-Whitney U) (Fig.3.7a). A comparison was made 
between the level of acetate measured in E. coli (16.6mM) and non-E. coli 
(14.7mM) infected urine, to determine whether acetate excretion was species 
specific. However, there was no significant difference between these two 
groups (Mann-Whitney U) (Fig.3.7 b).  
To determine if the acetate was produced in the urine due to ethanolamine 
metabolism, the concentration of ethanolamine detected in urine was 
correlated with the concentration of acetate detected in urine. There was 
very weak non-significant correlation between acetate and ethanolamine 
concentration in all urines (r=0.168, Spearmans Rank) (Fig 3.7c). 
Additionally, there was very weak non-significant correlation between acetate 
and ethanolamine in E. coli infected urine (r=0.207, Spearmans Rank) (Fig 
3.7 d). Finally, the correlation was measured between acetate level and 
expression of the eutR and eutB (Fig 3.7 e, f). There was weak, non-
significant correlation between acetate and eutR or eutB (r=0.162, r=0.157, 
respectively, Spearmans Rank). From this evidence it is concluded that 
acetate levels in the urine were not related to ethanolamine metabolism.  
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Figure. 3.7 Detection of breakdown products in infected urine. A. Acetate concentration 
of infected urines (n=52) vs non infected urines (n=12). B Acetate concentration of E. coli 
infected urines (n=19) vs non-E. coli infected urines (n=28). Mann Whitney-U test. C 
Correlation between acetate and ethanolamine in E. coli infected urine (n=19) D 
Correlation between acetate and ethanolamine in all collected urines (n=64). E The 
correlation between eutR gene expression and acetate levels. F The correlation between 
eutB gene expression and acetate levels. Correlation was measured by Spearman Rank.  
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3.3.5 Bacteria in the urine are associated with eukaryotic cells. 
Cells from whole urines collected from patients with suspected UTIs were 
transferred onto microscope slides by Cytospin and stained with the Kwik-
Diff™ staining protocol. Within the infected urines there were large numbers 
of eukaryotic cells, identified as epithelial cells and immune cells.  Bacteria 
within these urine samples were strongly associated with the eukaryotic cells 
(Fig 3.8), with transmission electron microscopy confirming association of 
bacteria with eukaryotic cells. These results are coupled with the detection of 
fimA RNA in E. coli infected urines. FimA is a major subunit of type 1 
fimbriae, which facilitated E. coli attachment to bladder cell epithelial (91). 
fimA RNA was detected in 56% of E. coli infected urines analysed by RT-
PCR with an average 10-fold higher expression relative to gyrA.  
79 
 
 
fimA
0
5
10
15
20
56%
R
e
la
ti
v
e
 e
x
p
re
s
s
io
n
Figure 3.8 Bacteria associated with eukaryotic cells in infected urine. Whole infected 
urines from CUH was centrifuged onto slide and strained with QwikDiff. A (40x), B (40x) 
and C (100x). D Bacterial pellets were imaged under Electron microscopy (courtesy of Dr 
M Liang University of Kent). E Expression of fimA in bacteria RNA (Fig. 3.3) relative to 
gyrA (n=24). Percentage of E. coli where gene expression was measured is indicated.  
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3.3.6 Influx of immune cells does not correlate to ethanolamine 
concentration 
Examining infected urine under the microscope, it is evident that there is an 
influx of immune and epithelial cells (Fig 3.8). As ethanolamine is a major 
component of the phospholipid bilayer of eukaryotic cells it can be 
hypothesised that there is a link between urinary tract inflammation and 
ethanolamine accessible for bacteria (132). The host response was 
investigated by measuring cytokine and proinflammatory markers by MSD 
ELISA. Of 10 cytokines and proinflammatory markers tested, three (IL-8, IL-
1β and IL-6) were detected in more than a half of the 64 urine supernatants 
tested, with 81%, 81% and 62.5% positive samples respectively. There was 
a significant increase in IL-1β (p=0.0048, Mann Whitney U) and IL-8 
(p<0.001, Mann Whitney U) in infected urines compared to non-infected 
urine. There was no significant difference in IL-6 expression, however the 
mean level in infected urine was 44.45pg ml-1 compared to 23.39pg ml-1 in 
control urine, therefore there was elevation of IL-6 during infection. When 
looking at the infected urine there was no significant difference in interleukin 
concentration between E. coli infected urine and non-E. coli infected urine.  
To explore the idea that ethanolamine comes from the breakdown of 
inflammatory cells the expression of cytokines was correlated against the 
level of ethanolamine detected in the urine. There was no significant 
correlation between cytokine expression and ethanolamine concentration. 
Therefore, it can be concluded that ethanolamine concentration in the urine 
is not influenced by inflammatory cells.  
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A IL-1β C IL-8 E IL-6 in infected urine (n=52) compared to non-infected (n=12). Detectable 
level of B IL-1β D IL-8 F IL-6 in E. coli infected urine (n=19) and non-E. coli infected urine 
(n=28).  Compared by Mann Whitney-U ** p≤0.01 *** p<0.001 
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Fig 3.10 Expression of pro-inflammatory cytokines does not correlate to 
ethanolamine concentration. Correlation of detectable level of A IL-1β, B IL-6 and C IL-8 
and ethanolamine in all urines (n=64). Correlation by Spearman’s Rank.  
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3.4 Discussion  
This study sought to characterise infected urines that were collected from 
CUH. The most prevalent bacteria isolated from infected urines was E. coli at 
55% (Fig 3.1). However, this is lower than the published prevalence of 75% 
(11). The 55% stated could be a low estimation for our urines as E. coli 
identified in mixed cultures isolated from infected urines were not included in 
this statistic and 16% of clinically infected urines did not yield isolates, 
probably because specimens were anonymised and not controlled for 
antimicrobial therapy.  
Analysing the genomes of the E. coli strains isolated from urine, the UPEC in 
this study were phylogenetically similar to previously published observations 
of urinary tract infection, where the majority of UPEC fall into phylogroups B2 
and D2 (38). In this sample there is a lower proportion of B2 strains (46%) 
(Fig. 3.2) than in urosepsis and urinary tract infection studies from the USA 
(67%-69%) (38, 198, 208), with a similar proportion to Slovenia (50%) (209), 
and more than China (19%)(199).  
While other pathotypes of E. coli have associated virulence genes, there is a 
lack of core virulence factors that determine pathogenicity in UPEC. 31 
putative urovirulence factors (PUF) have been identified by comparison of 
UPEC with E. coli isolated from other sites (208). In this study, PUF were 
strongly associated with phylogroup B2 strains, (Fig. 3.2) consistent with 
previous findings from a set of UTI isolates from the USA (38). However the 
study from the USA showed that the PUF were strongly associated with 
phylogroup B2, rather than uropathogenic strains, with similar levels of PUF 
identified in B2 UPEC and B2 strains not associated with UTIs (38). 
Additionally it was found that PUF profile does not correlate with virulence in 
animal models of UTI (38). In fact, PUF may be more important to the 
colonisation of the gut, as B2 strains are the most prevalent E. coli in the GI 
tract (210). Similarly, it was found that the metabolic loci proposed to 
promote growth in urine such as dsdCXA were also associated with 
phylogroup B2 rather than UPECs in general (Fig 3.3). In contrast, the eut 
operon is not associated with phylogenetic group but conserved within all 
UPEC (Fig 3.3).  
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The eut operon, is a 17-gene operon that facilitates the metabolism of 
ethanolamine to produced ammonia, acetyl Co-A and acetate that can be 
utilised by the bacteria as nitrogen and energy (further detail of ethanolamine 
metabolism is given in Chapter 1 and Chapter 4) (5). The eut operon is part 
of the core genome of E. coli however in some K-12 strains of E. coli the 
prophage CPZ-55 is located within the eut operon in an the opposite 
orientation to its transcription thus preventing the metabolism of 
ethanolamine (Appendix 4.5, Chapter 4) (204, 211, 212). In this sample of 
UPECs all strains contain a complete eut operon however one strain, U71, 
has a novel prophage insertion between eutA and eutB in the same location 
as CPZ-55 in MG1655 and BW23115 (Fig 3.4).  
In this study similar concentrations of ethanolamine were measured in 
infected urine (0.57mM) and non-infected urine controls (mean 0.65mM) (Fig 
3.5). This is consistent with previous reports on a smaller numbers of urine 
from healthy controls using different methodology such as NMR (0.38mM) 
and LC/MS (0.47mM) rather than HPLC (47, 213). Within the bovine intestine 
ethanolamine was measured at 2.2mM. Metabolising ethanolamine at this 
concentration provided enterohaemorrhagic E. coli with a competitive 
advantage in vitro (3). In comparison, D-serine which is regarded as an 
abundant substrate for E. coli metabolism in human urine has been reported 
at a mean concentration of 0.38mM (1, 62).  
 
There is evidence that ethanolamine in infected urine was sensed by E. coli 
with induction of the eut operon regulator eutR, and is also being 
metabolised, with induction of the ethanolamine deaminase component eutB 
correlated with measured ethanolamine levels in urine (Fig 3.6 b, c). 
Additionally, acetate, a breakdown product of ethanolamine was detected in 
urine (Fig 3.7). Acetate levels however were not significantly correlated to 
ethanolamine concentration or expression of the eut operon (Fig 3.7e). As 
acetate is also produced from the metabolism of amino acids and peptides, 
which are thought to be the main source of carbon for bacterial growth in 
urine, there are multiple potential sources for the acetate detected (49, 58). 
More recently acetate has being suggested as biomarker for bacteria growth 
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in urine (207). The acetate levels measured in this study however are 
considerably higher than those measured in recent publication which 
describe concentrations of between 0.017mM and 0.135mM detected in 
healthy urine, increasing to 1.15mM in infected urine (47, 207) (Fig. 3.7). In 
this study the level of acetate in urine is measured by HPLC while the 
previous studies use NMR (47, 207). Therefore, the discrepancy in acetate 
could be due to method sensitivity, however another detection method would 
be needed to confirm the acetate levels in these urines in this study.  
Ethanolamine is found naturally in the body in the form of 
phosphatidylethanolamine (PE). PE is the most abundant phospholipid in 
prokaryotic cells and the second most abundant phospholipid in eukaryotic 
cell (132). Within the GI tract available ethanolamine is assumed to derive 
from the breakdown of phospholipid from the rapid turnover of the epithelium 
and dietary phospholipid (134). There is a constant supply of ethanolamine in 
urine in both heath and infection (Fig 3.5), and the source in health seem 
unlikely to be cell turnover in the urinary tract, because this occurs at a 
relatively slow rate compared to the gastrointestinal tract. During UTIs there 
is an influx of inflammatory cells in response to pathogen pattern receptor 
activation (106) (Fig 3.8). The turnover of inflammatory cells, or the shedding 
of epithelial cells provoked by infection could provide a source of 
ethanolamine (42). However, there was no correlation between expression of 
IL-8, IL-6 and IL-1β, which are responsible for the influx of neutrophils, and 
concentration of ethanolamine detected in urine (Fig 3.10). As there is 
similarity in ethanolamine concentration between healthy and infected urine 
in this cohort, it can be predicted that ethanolamine is excreted through the 
kidney.  
There is however evidence of association of bacteria with host cell 
membrane in the urinary tract (Fig 3.8). Studies with enteropathogenic E. coli 
and enterohaemorrhagic E. coli has found that they preferentially bind to PE, 
over phosphatidylcholine and phosphatidylserine (214). Associated of 
bacteria with epithelial cells induce apoptosis which correlates with an 
increase in PE on the outer membrane facilitating increased binding to PE 
(215). More work however would be needed to see if this occurs with UPEC 
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in the urinary tract and whether bacterial binding of PE facilitated local 
ethanolamine metabolism without increasing urinary ethanolamine. 
In conclusion, this study has shown a consistent presence of ethanolamine 
has been detected in urine and provided evidence of ethanolamine 
metabolism in the urinary tract. The eut operon is conserved across all 
UPECs isolated in this study and is upregulated in this sample of infected 
urines. The upregulation detected in UPECs significantly correlated to the 
level of ethanolamine detected in urine (Fig 3.6). Published global expression 
analysis has provided evidence that while expression of the eut operon is 
dependent on host interactions, cytokine directed recruitment of inflammatory 
cells does not appear to contribute to eut expression in this study (17). Other 
host factors such as turnover of epithelial cells in response to bacterial 
infection could facilitate ethanolamine metabolism in the urine (42). 
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Chapter 4  An Investigation into the metabolism of 
ethanolamine by Uropathogenic E. coli  
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4.1 Abstract 
Ethanolamine is an amino alcohol present in abundance in cell membranes 
as phosphatidylethanolamine. Ethanolamine can be metabolised by 
Escherichia coli and Salmonella spp. as a source of carbon and nitrogen (13, 
143). The mechanism to metabolise ethanolamine by these Enterobacteria is 
encoded in the ethanolamine utilisation (eut) operon which is conserved 
across E. coli and Salmonella strains, however ethanolamine is not a 
preferred nutrient for growth (5). In the gastrointestinal (GI) tract, 
ethanolamine metabolism has been found to promote Enterohaemorrhagic 
E. coli (EHEC) and Salmonella typhimurium overgrowth to promote 
gastrointestinal infection (3, 4).  Extra-intestinal E. coli that naturally resides 
in the GI tract can colonise the bladder to cause urinary tract infections. 
While it is clear that ethanolamine is present from food and cell breakdown in 
the nutrient rich gut, until recently its presence in the relatively nutrient poor 
environment of urine was underappreciated. Ethanolamine has been 
measured in our study and others at average concentrations of 0.57mM in 
urine (Chapter 3 and (47)) and expression of the E. coli eut operon was 
detected in RNA from infected urine (Chapter 3 and(17)).  
In this study, uropathogenic E. coli (UPEC) isolated from infected urines 
were evaluated for their ability to utilise ethanolamine. The majority of the 
isolated UPECs were able to utilise ethanolamine as a nitrogen source in 
modified M9 minimal media (Mod M9). Four isolates that demonstrated 
growth enhancement with ethanolamine in Mod M9 were grown using an in 
vitro urine model using artificial urine medium (AUM) (185) and confirmed a 
similar growth advantage. Subsequently, knock-out mutants in the eut 
operon were created. These strains were unable to utilise ethanolamine in 
vitro and were out-competed by their wild-type parental strain in AUM. 
UPECs were also able to metabolise physiological levels of ethanolamine to 
promote a biologically significant growth advantage. This study found that 
ethanolamine in the urinary tract is a reliable nutrient source for E. coli via 
microcompartment-mediated metabolism.  
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4.2 Introduction  
Urinary tract infections (UTIs) are caused by bacteria ascending the urethra 
and migrating to the bladder where they replicate and colonise to cause 
infection (11). Seventy-five percent of non-complicated UTIs are caused by 
UPECs, a type of extra-intestinal E.coli (ExPEC), which reside harmlessly in 
the gut (1). Within the gut UPECs reside in the nutrient rich mucus lining, in 
contrast to the nutrient-limited environment of the urinary tract (51). Recent 
studies have found that UPECs undergo rapid growth in the urinary tract, 
compared to commensal strains and asymptomatic bacterial colonising 
strains. This suggests that rapid metabolic adaptation and proliferation in the 
urinary tract is a key part of UPEC pathogenesis (50).   
Urine is the main source of nutrients for extracellular bacteria in the urinary 
tract. It is a complex mixture of amino acids, short peptides, and limited iron 
availability with moderate oxygenation (47).  Competition studies in a mouse 
model of UTI has investigated UPEC requirements for central carbon 
metabolism in the urinary tract. Mutations that interrupt gluconeogenesis 
(pckA) and the TCA cycle (sdhB) have been shown to reduce fitness of 
UPEC in mouse models of bladder and kidney infection (12). This is in 
contrast to the nutrient-rich intestine where glycolysis (pgi) or the Entner-
Douderoff (edd) pathway are required for colonisation fitness (55). In 
addition, deletion of the peptide transport proteins (dppA or oppA) also 
reduces fitness of UPEC in this model, suggesting that peptides and amino 
acids are crucial sources of carbon in the urinary tract (12). Genes involved 
with amino acid metabolism are upregulated during growth in urine including 
the D-serine deaminase (dsd) operon which regulates the metabolism of D-
serine (59, 62). D-serine, one of the most abundant amino acids in the urine 
present in urine, is broken down to pyruvate and ammonia, and can be 
utilised by E.coli as a sole source of carbon and nitrogen (216).  
Ethanolamine is an amino alcohol commonly found in the phospholipid layer 
of eukaryotic and prokaryotic cell membranes in the form of 
phosphotidylethanolamine (PE) (132). Ethanolamine can be broken down by 
bacteria to be used as a source of carbon or nitrogen (2, 3, 13, 144).  EHEC, 
Salmonella spp. and Listeria spp. utilise the abundance of ethanolamine in 
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the gut to out-compete commensal bacteria (3, 4). As metabolising 
ethanolamine provides a competitive advantage to pathogenic bacteria, it 
has been linked to pathogenesis in gastrointestinal infections (3, 4, 167).  
Metabolism of ethanolamine is controlled in E. coli by a conserved 17-gene 
ethanolamine utilisation operon (eut operon) described first in Salmonella 
enterica (5). In brief, the operon is controlled by the positive regulator eutR, 
which is activated in the presence of ethanolamine and cobalamin (141). 
Ethanolamine is broken down to ammonia, ethanol and acetyl-coenzyme A 
(acetyl-CoA) which can enter the TCA and glyoxylate cycle or can be utilised 
for lipid biosynthesis (151). During the first reaction ethanolamine is broken 
down to acetaldehyde by the ethanolamine ammonia lyase (EutBC) 
releasing ammonia, a convenient source of nitrogen for bacteria (143). 
Acetaldehyde is then converted to acetyl-CoA by the action of acetaldehyde 
dehydrogenase (EutE) and coenzyme A (CoA) in an NAD+ dependant 
reaction (13).  NAD is subsequently oxidised for this by the action of the 
alcohol dehydrogenase EutG which converts acetaldehyde to ethanol 
consuming NADH in the process. Under energy limiting conditions acetyl Co-
A is converted into acetyl-phosphate by phosphotransacetylase (EutD) and 
ultimately to acetate with generation of ATP either by microcompartment-
associated acetate kinases EutP and EutQ or cytoplasmic acetate kinase 
AckA (147, 150, 206). Acetate is excreted but can be recaptured when it is 
needed (148, 205). 
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Figure 4.1 A. Configuration of the eut operon in E. coli. B. Schematic of 
ethanolamine metabolism in E. coli. Ethanolamine breakdown is carried out 
in microcompartments in the cytoplasm (151). 
 
 
The enzymatic reactions for ethanolamine degradation are physically 
encased by a proteinaceous structure called a bacterial microcompartment 
(BMC).  The structural proteins that form the thin shell of the Eut BMC are 
encoded by five of the 17 genes of the eut operon (Fig 4.1a) (5). These 
structures have been found in many phyla of bacteria however the functional 
role of the MCP structure has not been fully elucidated despite various 
hypotheses presented (14, 15). This is discussed in more detail in Chapter 1. 
Induction of the eut operon has been identified in the urinary tract. An in vivo 
mRNA screen found that the eut operon was upregulated in human urine of 
active UTI (see Chapter 3). Competition assays revealed reduced fitness of 
the Eut operon knockouts compared to wild type in a mouse UTI model (17). 
In support of these findings, a recent study has found that the eut operon is 
92 
 
important for the avoidance of the innate immune response in the urine 
leading to the successful colonisation of the bladder (10). While eut operon 
function has been found to be important for UPEC colonisation of the bladder 
there is little evidence on whether ethanolamine is used as a nutritional 
source in the urine, as previously shown in the gut (3). 
In Chapter 3, UPEC strains were characterised as having a conserved eut 
operon as a part of their core genome, however only 57% of the strains had 
an intact D-serine metabolism operon (Chapter 3). Additionally, 
ethanolamine was detected in urine from 64 patients at a mean 
concentration of 0.57mM (Chapter 3), consistent with findings from a urine 
metabolome study conducted on 22 healthy volunteers (47). This is higher 
than any individual amino acid present in the urine (47). In this study, UPEC 
isolated from infected urines were assessed for their ability to utilise 
ethanolamine as a nitrogen or carbon source. An in vitro model using an 
artificial urine medium was developed to determine if there is a growth 
advantage for UPEC in urine-simulated conditions when ethanolamine is 
added. Biochemical assays were used to identify if any advantage observed 
was accompanied by the metabolism of ethanolamine. Finally, this chapter 
investigates whether ethanolamine provides a nutritional competitive 
advantage for UPEC in vitro. 
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4.3 Results 
4.3.1 Clinical UPEC strains can utilise ethanolamine as a sole 
nitrogen source but not a carbon source in minimal media. 
The ability of the isolated clinical UPEC’s to utilise ethanolamine as a carbon 
and nitrogen source was investigated by growing the clinical isolates in 
modified M9 minimal media (Mod M9) supplemented with 10mM 
ethanolamine. As previous studies have determined that E. coli can 
favourably utilise ethanolamine as a nitrogen source (3, 13), the UPEC 
isolates were screened for utilisation of ethanolamine as a sole nitrogen 
source in Mod M9 with glycerol as a carbon source.  It was found that the 
92% of the 48 UPECs isolated were able to utilise ethanolamine as a 
nitrogen source (Appendix 4.1). The growth increment conferred by addition 
of ethanolamine differed between the strains, and the increase in Maximum 
optical density at 600nm (OD600nm) between cultures with ethanolamine and 
without ethanolamine was used as a measure of effective ethanolamine 
utilisation (Fig 4.2a). U1, U13, U17 and U38 were selected to investigate 
whether they could utilise ethanolamine as a sole carbon source considering 
they effectively utilised ethanolamine as a nitrogen source (Fig 4.2b). U1 and 
U17 could not utilise 10mM ethanolamine as the sole carbon source (Fig 
4.2c). U13 and U38 showed a very slight increase in OD600nm 30hrs after 
inoculation.  
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A. 
B. C. 
Figure 4.1 UPEC are able to utilise ethanolamine as a nitrogen source in modified 
M9 media but not as a carbon source. A Difference in Maximum optical density 
measured at 600nm (Max OD
600nm
) in ammonia-free modified M9 media comparing the 
absence and addition of 10mM Ethanolamine. B Growth of selected UPECs in 
ammonia free modified M9 when 10mM ethanolamine is supplemented. C Growth of 
selected UPECs in carbon free modified M9 media supplemented with 10mM 
ethanolamine.  Values are Mean ± SEM n≥3. 
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4.3.2 Ethanolamine in Modified M9 and Artificial Urine Medium is 
metabolised by UPEC strains 
UPECs were grown in Mod M9 and an artificial urine medium (AUM) which 
mimics the composition of urine (Chapter 2) (185). The four selected strains 
showed enhanced growth in both media when supplemented with 10mM 
ethanolamine (Fig 4.3) compared to the corresponding media without 
ethanolamine. Unlike Mod M9, AUM is able to support bacterial growth 
without the addition of ethanolamine. To investigate how ethanolamine is 
used in these growth conditions, the concentration of ethanolamine and its 
metabolic products acetate and ethanol were measured over time using 
HPLC analysis. The concentration of ethanolamine decreased over the 32Hr 
growth period at a rate of 0.67mM/hour when grown in Mod M9 and fell 
below 2mM after 16hrs incubation for all strains (Fig 4.4 a, c, e, g). 
Ethanolamine levels started to decrease as the bacteria left lag phase (8hrs) 
and enter exponential growth in tandem with acetate and ethanol production. 
Growth continued after all ethanolamine was consumed. In Mod M9 maximal 
acetate levels were approximately equimolar to the initial ethanolamine 
concentration and peaked for 3 of the 4 strains at 18hrs. Maximal ethanol 
levels likewise occurred at 28hrs but were approximately twice the initial 
molar concentration of ethanolamine. When the four UPEC strains were 
grown in AUM a shortened lag phase and increased rate of ethanolamine 
metabolism was noted than in ModM9 (Fig 4.4 b, d, f, h). Ethanolamine 
levels were almost completely diminished for three out of four strains by 
12Hrs in AUM at a maximum rate of 1mM/hour. Ethanol levels reached their 
peak by 24hrs. Growth of the bacteria continued after ethanolamine was 
depleted. Unlike Mod M9, baseline levels of acetate were detected, and 
maximum levels were detected after 20hrs (Fig 4.4b, d, f, h).   
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A. 
B. 
Figure 4.2 Ethanolamine promotes a growth advantage in Modified M9 and 
Artificial urine medium (AUM). Growth of selected UPEC in: A. Ammonia free 
modified M9 media (dashed line) and ammonia free modified M9 media with10mM 
Ethanolamine (solid line) B. AUM (dashed line) and AUM with 10mM Ethanolamine 
(solid line). Growth measured by optical density at 600nm (OD600nm). Values are Mean 
± SEM. N≥3.  
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Figure 4.3 Ethanolamine is broken down by UPEC to release acetate and 
ethanol. A,C,E and G.  Growth of UPEC’s in modified M9 with 10mM ethanolamine 
(black) and concentration of ethanolamine (Eth)(green), acetate (red) and ethanol 
(blue) over the 32hrs. B,D,F and H Growth of UPEC’s in AUM with 10mM 
ethanolamine (black) and concentration of ethanolamine (green), acetate (red) and 
ethanol (blue) over 32hrs . Values are Mean ± SEM. N=3.  
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4.3.3 Construction of eut mutants in clinical isolate strain U1  
To assess the importance of ethanolamine metabolism in UPEC, in-frame 
knock-out mutants were created in U1 using P1cm1-directed transduction as 
described in Chapter 2. Strains from the KEIO collection of single gene 
knock-out mutants were used as donor strains to replace genes in wild-type 
U1 with a kanamycin cassette to create knock-out mutants by homologous 
recombination (183)(Fig 4.5a). Mutation was achieved in the eut operon 
regulator, eutR, the major subunit of the ethanolamine ammonia lyase 
enzyme, eutB, which facilitates the breakdown of ethanolamine to 
acetaldehyde and ammonia, and the acetaldehyde dehydrogenase, eutE, 
which is needed to generate acetyl-CoA from acetaldehyde. In each case a 
single kanamycin cassette insertion, flanked by Flp recognition site, replaced 
the expected gene and was confirmed by whole genome sequencing (183). 
However, in U1∆eutR there was an additional prophage insertion between 
eutA and eutB. This prophage is identical to the prophage found in the K12 
lab strain MG1655 with open reading frames in reverse orientation to the eut 
operon which prevents downstream transcription of the operon, and prevents 
utilisation of ethanolamine (Appendix 4.4) (141). To complement the single 
knock-out mutants, another E. coli library was utilised. The ASKA clones are 
a collection of individual genes ligated onto pCA24N under the control of the 
pTn5 lac-promotor that is activated by Isopropyl-β-D –thiogalactopyranoside 
(IPTG) (Fig 4.5c). The cognate plasmids were electroporated into the 
relevant knock out mutants and the presence of the plasmid was confirmed 
by colony PCR. 
The strains were screened for loss of fitness by growth in LB prior to 
screening for loss of function. The single knock-out mutants did not display a 
fitness deficiency in LB compared to the wild-type. The complemented 
mutants did display a slight loss of fitness (Fig 4.5b). There is evidence of 
lethal over-expression of gene using the ASKA clones, therefore multiple 
concentrations of IPTG were tested for their ability to complement U1∆eutB 
(188). Induction of the gene with 0.01mM IPTG restored the phenotype in 
Mod M9 with 10mM ethanolamine (Fig 4.5d). All strains were the assessed 
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for their ability to utilise ethanolamine by growth in Mod M9 with 10mM 
ethanolamine, with complemented strains being induced by 0.01mM IPTG 
(Fig 4.5e). The U1∆eutR and U1∆eutB both displayed a loss of growth 
phenotype compared to the wild type (Fig 4.5e). This phenotype was 
restored by complementation in U1∆eutB and was not restored in U1∆eutR 
as expected due to the presence of the prophage in the knock-out.  
However, the eutE mutant grew to an OD600nm similar to the wild-type (Fig 
4.5e). This confirms that the mutants are nonpolar as the transcription of the 
downstream genes eutB and eutC that encode the ethanolamine ammonia 
lyase enzyme, required for the breakdown of ethanolamine to acetaldehyde 
and ammonia, must be active to provide ammonia for the strain to grow on 
nitrogen limited Mod M9 with ethanolamine (142). In addition, the ∆eutE 
mutant and complemented strain had a faster growth rate compared to the 
wild type.  
100 
 
 
 
Figure 4.4 Construction of knock out mutants using P1 transduction. A 
Schematic of cassette insertion following P1 transduction. B Diagram of 
ASKA plasmid pCA24N (188). C Growth of U1, U1 mutants and 
complemented strains in LB over 36 hours. D Growth of U1∆eutB+peutB with 
different concentration of IPTG. E Growth of U1, U1 mutants and 
complemented strains in Mod M9 with 10mM ethanolamine. Values are 
means ±SEM. N=3 
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4.3.4 eutR and eutB are essential for ethanolamine metabolism in 
Mod M9 and AUM 
The function of eutR, eutB and eutE in ethanolamine metabolism was 
investigated by comparing substrate utilisation in the wild type and single 
gene knock-out mutants (Fig 4.6a). In Mod M9 medium, ethanolamine was 
consumed by U1 and U1∆eutE strains with the concentration of 
ethanolamine decreasing over 24hrs (Fig 4.6b). This indicates that EutBC 
was functional in both U1 and U1∆eutE. The breakdown of ethanolamine 
began between 8 and 12hrs in U1 and after 4hrs in U1∆eutE, corresponding 
to exponential growth in the media (Fig 4.6b). After 24hrs ethanolamine was 
depleted in the media as the bacteria entered lag phase (Fig 4.6).  U1∆eutB 
and U1∆eutR however were unable to consume ethanolamine (Fig 4.6b) and 
were unable to grow in Mod M9 with ethanolamine as a nitrogen source (Fig 
4.6a). 
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Figure 4.6 Ethanolamine is utilised as a nitrogen source in Mod M9. A. 
Growth of U1, U1ΔeutR U1ΔeutB and U1ΔeutE in modified M9 with 10mM 
ethanolamine. B. Schematic of ethanolamine metabolism pathways with genes 
knocked out highlighted in red. C. HPLC analysis of ethanolamine concentration 
in mod M9 with 10mM ethanolamine over 24 hrs. Values are Mean ± SEM. N=3.  
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The ability of the mutants, and complemented mutants to grow in AUM was 
compared to the wild type strain (Fig 4.7). When grown in AUM with 10mM 
ethanolamine all the strains had reduced growth compared to the wild type 
and match the maximum OD600nm of the wild type when ethanolamine was 
not supplemented (Fig 4.7a). Interestingly, U1∆eutE, which was not impaired 
for growth in Mod M9 medium with ethanolamine, was impaired compared to 
the wild-type in AUM plus ethanolamine (Fig 4.7a). The growth phenotype 
was restored to wild-type levels for all of the complemented mutants when 
the cognate ASKA plasmid was induced with 0.01mM IPTG. This included 
U1eutR/pCA24N::eutR, despite the prophage insertion (Fig 4.7a).   
The ability of U1 and its corresponding mutants to utilise ethanolamine when 
supplemented in AUM was examined (Fig 4.7). The U1∆eutE strain 
metabolised ethanolamine in AUM, however, unlike when grown in Mod M9, 
this did not translate to a growth phenotype similar to the wild type (Fig 4.7a). 
This suggests that ammonia produced from ethanolamine metabolism is not 
the primary cause of U1 growth enhancement when ethanolamine is added 
to AUM. Rather onward metabolism of acetaldehyde, derived from 
ethanolamine metabolism, is utilised for carbon or energy (Fig 4.1).   
U1∆eutB and U1∆eutR did not metabolise ethanolamine, and growth of 
these strains was similar to U1 grown in AUM without ethanolamine (Fig 
4.7a). Complementation of U1∆eutB restored ethanolamine metabolism, 
while complemented U1∆eutR/pCA24N::eutR showed very little utilisation of 
ethanolamine. A significant difference in the percentage of ethanolamine 
used at 24 hrs was found between the wild type and U1∆eutB, U1∆eutR and 
U1∆eutR/pCA24N::eutR strains.  Despite this, the growth phenotype was 
restored for U1∆eutR/pCA24N::eutR as well as the ∆eutB mutations by 
complementation.  
Colony PCR of U1∆eutR/pCA24N::eutR after growth in AUM with 10mM 
ethanolamine confirms that the prophage insertion is present (Appendix 4.5). 
This data indicates that the restored growth phenotype observed in the 
U1∆eutR/pCA24N::eutR is not primarily due to restoration of ethanolamine 
consumption. Instead growth could be restored by increased metabolism of 
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intermediates further down the ethanolamine degradation pathway such as 
acetaldehyde, or by EutR mediated regulation of an additional operon.  
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Fig4.6 Ethanolamine does not increase growth in eut knock out mutants in AUM 
A. Growth of all strains in AUM with 10mM ethanolamine. B. HPLC analysis of 
ethanolamine concentration in AUM with 10mM ethanolamine over 24 hours. C. 
Change in ethanolamine after 24hours. 1-way ANOVA. ***P<0.001. Values are Mean ± 
SEM. N=3 or more.  
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4.3.5 Prophage can excise in U1∆eutR/pCA24N::eutR when grown in 
Mod M9 with ethanolamine but not when grown in AUM with 
ethanolamine  
The introduction of the CPZ-55 prophage into the genome of U1 during 
transduction to form the U1∆eutR prevents complementation of the strain in 
Mod M9. To investigate whether the prophage could be excised with 
prolonged nutritional stress, U1∆eutR/pCA24N::eutR, was grown for 48hrs in 
Mod M9 with 10mM ethanolamine. After 30hrs incubation in Mod M9 with 
10mM ethanolamine growth of U1∆eutR/pCA24N::eutR was detected (Fig 
4.8a).  After 48hrs the bacterial cultures were grown in Mod M9 with 10mM 
ethanolamine for a further 24hrs before the strains were screened for the 
presence of the prophage by colony PCR, using primers that amplify the 
border between the prophage and eutB. Two of the three colonies were 
negative for the presence of the prophage (lane 9 and 10, Fig 4.8b) while the 
kanamycin cassette that replaces eutR was still present in the bacterial 
genome (Lanes 1-3, Fig 4.8b). Therefore, this suggest that in situations of 
nutritional stress the prophage can excise from the eut operon. Interestingly, 
prophage excision when U1∆eutR/pCA24N::eutR was grown in AUM plus 
ethanolamine was not detected (Appendix 4.5).   
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Figure 4.8 Prophage CPZ-55 excises from U1∆eutR/pCA24N::eutR during nutrient 
stress. A. Growth of U1∆eutR/pCA24N::eutR in Mod M9 with 10mM ethanolamine for 
48 hours. B. Colony PCR of strains collected after 48hrs growth. Lanes 1-6 amplify 
region over Kanamycin cassette. Lanes 8-13 amplify region over CPZ-55 and eutB 
boarder. C. Schematic of PCR amplification over prophage border. Lanes are as 
follows:  
1./8. U1∆eutR/pCA24N::eutR.1 2./9. U1∆eutR/pCA24N::eutR.2  
3./10. U1∆eutR/pCA24N::eutR.3 4./11. U1∆eutR/pCA24N::eutR (before growth)  
5./12. U1 6./13. H2O. Values are Mean ± SEM N ≥3. 
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4.3.6 eut operon is up regulated in U1 when grown in AUM 
supplemented with ethanolamine  
Expression of the eut operon was investigated in AUM to determine the 
involvement of the eut operon in the metabolism of ethanolamine.  The eut 
operon expression in U1 was measured by qRT-PCR and compared to the 
geometric mean of gyrA and rrsA housekeeping genes via 2-∆∆CT (190, 
217). Gene expression was measured at 4 hrs, 8 hrs and 24 hrs incubation, 
corresponding to different phases of growth and ethanolamine breakdown as 
determined by OD600nm measurements and HPLC (Fig 4.3b). Relative 
expression of eut genes, eutR, eutB, eutE and eutS in AUM with 
ethanolamine were compared to relative expression during exponential 
growth in AUM. All genes are significantly upregulated in U1 when 
ethanolamine is present at 4hrs and 8 hrs incubation; eutR, eutB and eutE 
were increased approximately 15-fold (Student t-test or Mann Whitney U 
when data is not normally distributed) (Fig 4.9a). eutS displayed 130-fold 
increase in expression (Fig 4.9a). At 24 hrs the expression of these genes 
decreases, which corresponds to ethanolamine depletion (Fig 4.3b; 4.9a).  
Expression of the eut operon was also measured in the knock-out mutants 
and compared to expression observed in the wild type. Expression was 
measured at 4 hrs when all strains were in exponential phase. The data 
shows that there is negligible induction of the eut operon by ethanolamine in 
the U1∆eutR. These results confirm the positive regulation of the operon by 
eutR as described by Roof and colleagues (141).  In U1∆eutB, eutR and 
eutE were upregulated by ethanolamine, 10 and 6-fold respectively, 
confirming there is no polar effect associated with the insertion of the 
kanamycin cassette. However, the upregulation of these genes was not 
significant (Fig 4.9) (Mann-Whiney U). Likewise, eutB was upregulated by 
the addition of ethanolamine in the U1∆eutE strain. This suggest that 
ethanolamine ammonia lyase enzyme that metabolises ethanolamine to 
acetaldehyde should still be expressed in U1∆eutE (Fig 4.9) (Mann Whitney 
U, p=0.0028). 
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Figure 4.9 The eut operon is upregulated in AUM with the addition of 10mM 
ethanolamine. A. Relative expression of eutR, eutB, eutE and eutS in U1 grown in AUM 
with and without 10mM ethanolamine. B. Schematic of the eut operon. C Relative 
expression of eutR, eutB and eutE in B U1∆eutR C. U1∆eutR and D. U1∆eutR after 4 
hours growth in AUM with and without 10mM ethanolamine. Expression is measured 
relative to the geometric mean of rrsA and gyrA.  Values are Mean ± SEM. N=3.  Student 
t-test (or Mann Whitney U where sample is non parametric appropriate) * p<0.05, 
**p<0.01, ***p<0.001. 
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4.3.7 Microcompartments are visible during growth in AUM with 
10mM Ethanolamine 
Gene expression data showed that eutS which encodes a shell protein for 
the Eut bacterial microcompartment was highly upregulated when U1 was 
grown in AUM with ethanolamine (Fig 4.9a). To investigate whether these 
microcompartments were visible in U1 in the presence of ethanolamine, 
bacterial pellets were harvested after 8 hours incubation in AUM with 10mM 
ethanolamine and fixed for transmission electron microscopy. Imaged 
sections show numerous straight-edged polyhedral structures 100-150nm in 
diameter in most cells visualised (Fig 4.10a). This is classical 
characterisation of the bacterial microcompartment (Fig 4.10a) (165). These 
structures were not visible in U1 when grown in AUM without ethanolamine 
or U1∆eutR when grown in AUM with or without ethanolamine (Fig 4.10 b, c 
and d). This provides further evidence of microcompartment-mediated 
metabolism of ethanolamine in E. coli. 
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A B 
C D 
Fig4.10 Transmission electron microscopy of A U1 grown in AUM for 8hrs B 
U1 grown in AUM with 10mM ethanolamine for 8hrs. C U1∆eutR in AUM for 
8hrs. D U1∆eutR in AUM with 10mM ethanolamine for 8hrs. Arrow point to 
microcompartments.   
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4.3.8 The physiological concentration of ethanolamine in urine 
increases UPEC growth in vitro 
In Chapter 3 of this thesis ethanolamine was measured in infected urine by 
HPLC and detected at a mean concentration of 0.567mM. To test the ability 
of U1 to metabolise ethanolamine at this physiological level, U1 was grown in 
Mod M9 with 0.5mM ethanolamine in parallel to the U1 knock-out mutants 
and their complemented strains for 24hrs (Fig 4.11a). At this concentration 
U1 has a growth advantage over the eutR and eutB knock-out mutants, 
which grow similarly to U1 in the absence of ethanolamine. U1 displays 
similar growth at 20hrs compared to the eutE mutant, and the eutB-
complemented clone, however the eutE mutant and its complemented clone 
have a higher growth rate than U1 for the first 10 hours (Fig 4.11a).  
 
 
Figure. 4.11 Physiological levels of ethanolamine promote a growth advantage for U1 
and complemented mutants. Growth of U1 and related strain grown in Mod M9 with 0.5mM 
Ethanolamine. Values are Mean ± SEM. N=3. 
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U1 was also grown in AUM with ethanolamine at this concentration. The 
difference in growth between 0 and 0.5mM ethanolamine measured by 
OD600nm is small but there is a positive increment conferred by additional 
ethanolamine (Fig 4.12a). This difference in U1 growth by OD600nm was 
calculated to be significant at 8hrs (p<0.001) and 24hrs (p<0.05) (t-test). 
When growth of U1 was measured by viable count (CFU ml-1), an increase in 
bacterial number was seen with additional ethanolamine. There was a 
significant difference in CFU ml-1 at 8hrs with an increase of 1.5x108 CFU ml-
1 (p<0.05, Student t-test) (Fig 4.12a). In contrast the eut mutants do not 
display a consistent growth difference with the addition of 0.5mM 
ethanolamine when measured by OD600nm or viable count (Fig 4.12b, c and 
d). 
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Figure .4.12 Growth of A U1; B U1∆eutR C U1∆eutB D U1∆eutE in 
AUM+0.5mM ethanolamine measured by Optical Density (OD
600nm 
(Solid line) 
and CFU ml
-1
 (Dashed line). Difference in OD
600nm
 and CFU ml
-1
 was measured 
by Student t-test:  OD
600nm
.  (* p<0.05, ***p<0.001), CFU ml
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(^ p<0.05) 
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 Mod M9 10mM  Mod M9 0.5mM  AUM 10mM AUM 0.5mM 
U1 + + + + 
U1∆eutR - - - - 
U1∆eutB - - - - 
U1∆eutE + + - - 
U1∆eutR/pCA24N 
::eutR 
 +* - + ND 
U1∆eutB/pCA24N 
::eutB 
+ + + ND 
U1∆eutE/pCA24N 
::eutB 
+ + + ND 
Table 4.1 Summary of growth of U1 strains in media with ethanolamine.  + = 
growth enhancement compared to growth without ethanolamine. - =no growth 
enhancement compared to growth without ethanolamine. ND=no data. *Growth 
enhancement only observed after 30 hours 
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4.3.9 Ethanolamine provides a competitive advantage for UPEC in 
AUM 
To determine whether ethanolamine consumption provides a competitive 
advantage to UPECs, U1 was co-incubated in AUM containing ethanolamine 
with each of the mutants. The bacteria were incubated for 24hrs before being 
re-inoculated into fresh AUM and ethanolamine for a second cycle of growth 
to emphasise any competitive advantage. When incubated with 10mM 
ethanolamine, the wild type had a clear advantage over all mutants after 
36hrs (Fig 4.13). There is a significant difference in CFU ml-1 after 32hrs of 
incubation with U1∆eutR (p<0.01, Student's t-test), which is also seen from 
incubation with U1∆eutB (p<0.05, Student's t-test). However, growth of U1 
with U1∆eutE, conferred a growth advantage beginning at 12hrs with 
significant differences measured at most time points (Fig 4.13 f). When the 
bacteria are grown in physiological levels of ethanolamine the wild type does 
not appear to have a competitive advantage in this model when raw counts 
are used. (Fig 4.13)   
The competitive index was calculated for the competition of wild type U1 and 
mutants in AUM with the different concentrations of ethanolamine. The 
competitive index was calculated, as specified in Chapter 2, and competitive 
indices of less than 1 represent U1 outcompeting the mutant. With the 
addition of 10mM ethanolamine the CI indicates that the wild-type 
outcompetes the mutant strains at all time points tested (Table 4.3). In 
contrast the CI calculated when grown in AUM with 0.5mM ethanolamine 
shows that the wild type has an advantage over the mutants at later time 
points however the advantage is variable over the 48hour period, indicating 
0.5mM does not give U1 a clear growth advantage over its isogenic mutants 
(Table 4.2).   
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Fig4.13 Ethanolamine provides a competitive advantage for the wild type in AUM. 
Competition of U1 vs A. U1∆eutR with 0.5mM ethanolamine B U1∆eutR  with 10mM 
ethanolamine C U1∆eutB  with 0.5mM ethanolamine D U1∆eutB  with 10mM 
ethanolamine E U1∆eutE  with 0.5mM ethanolamine F U1∆eutE  with 10mM 
ethanolamine. Student t-test or Mann Whitney U test (where appropriate) were used to 
compared CFU. *p<0.05, **p<0.01, ***p<0.001. Values are Mean ± SEM. N=3.   
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 Incubation time (hrs)  
Bacterial 
Strains 12 24 24 (I) 28 32 36 48 
U1/U1∆eutR 0.95 0.67 1.89 0.81 0.80 0.71 0.79 
U1/U1∆eutB 1.68 2.44 0.74 0.69 1.35 1.27 0.61 
U1/U1∆eutE 0.68 1.23 0.71 0.40 0.60 1.06 0.55 
 
 
 
 
  Incubation time (hrs)         
Bacterial 
Strains 12 24 24 (I) 28 32 36 48 
U1/U1∆eutR 0.37 0.22 0.13 0.15 0.11 0.09 0.10 
U1/U1∆eutB 0.51 0.72 0.42 0.52 0.19 0.42 0.40 
U1/U1∆eutE 0.36 0.48 0.36 0.40 0.28 0.24 0.26 
 
Table 4.3. Competitive index of strains grown in co-culture in AUM with 
10mM ethanolamine. CI is calculated as described in Chapter 2. CI below 0.8 
are in bold. 24 (I) indicates that the bacteria were subcultured. Values are Mean 
± SEM. N=3.  
Table 4.2. Competitive index of strains grown in co-culture in AUM with 0.5mM 
ethanolamine. CI is calculated as described in Chapter 2. CI below 0.8 are in bold. 24 
(I) indicates that the bacteria were subcultured. Values are Mean ± SEM. N=3.  
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4.4 Discussion 
During a UTI there is a lack of a dominant virulence factor associated with E. 
coli pathogenesis and colonisation of the bladder. Recent research into 
UPEC pathogenesis has shifted focus from virulence factors to metabolism 
(12, 45). In Chapter 3 of this thesis and other studies, it has been established 
that the eut operon is up-regulated in infected urine (149). While 
ethanolamine metabolism has been found to provide a nutritional advantage 
for pathogenic bacteria to compete with commensal bacteria in the gut, there 
are few studies exploring the role of ethanolamine metabolism in the bladder 
(3, 4). In this study the effect of ethanolamine on the growth of UPECs in 
vitro was investigated. 
Previously, whole genome analysis of UPECs collected in this thesis 
established that 47 out of 48 E. coli’s have intact uninterrupted eut operons 
(Chapter 3). Therefore, the strains have the ability to metabolise 
ethanolamine to ammonia and acetate to use as a source of nitroge n and 
carbon (Fig 4.3) (142, 148).  As E. coli lack the urease enzyme which breaks 
down urea, the main source of nitrogen in the urine, it can be assumed that 
urine is a relatively nitrogen limited environment for UPEC. Additionally, the 
high-ammonium affinity glutamine synthase and glutamate oxo-glutarate 
aminotransferase pathway (GS/GOCAT) for nitrogen assimilation in low 
nitrogen environments is induced in E. coli infected urine (59, 65). Previous 
work on enteric E. coli has found that ethanolamine can be utilised by E. coli 
as a sole source of nitrogen when supplemented at 30mM (3). In this study, 
90% of the isolated UPECs were able to utilise ethanolamine as a sole 
nitrogen source at 10mM concentration in vitro (Fig 4.2).  
The well characterised UPEC CFT073 has been shown to grow on acetate 
released during from amino acid metabolism (58). As ethanolamine is 
metabolised to acetate it is hypothesised that UPECs can use ethanolamine 
as a sole carbon source.  However, UPECs in this study could not utilise 
10mM ethanolamine as a carbon source to promote significant growth in vitro 
(Fig 4.2c). While ethanolamine has reported to be utilised as a carbon source 
in Salmonella spp. at a concentration of 20mM (148, 149), higher 
concentrations of ethanolamine have been reported for successful E. coli 
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utilisation as a sole carbon source (82mM, 1g L-1) (218). O157:H7 EHEC 
strain EDL933 is unable to utilise ethanolamine as a sole carbon source 
even at this higher concentration despite evidence of the eut operon activity 
(3). Mutational studies in Salmonella enterica show that growth on 
ethanolamine as a carbon and energy source proceeds via the glyoxylate 
bypass and the Krebs cycle (148). Acetyl-coA synthetase (Acs) is required to 
utilise ethanolamine as a carbon source through the operation of an acetate 
switch (leading to eventual uptake of acetate from the culture medium)(148). 
Therefore, more research into these pathways in the UPECs would be 
needed to determine why ethanolamine cannot be utilised as a sole carbon 
source.  
To explore the metabolism of UPECs in urine, an in vitro model using an 
artificial urine medium was used in this study to mimic the nutrient availability 
in urine(185). Supporting previous work, mutational studies of U1 provide 
evidence that the ethanolamine ammonia lyase enzyme is crucial for E. coli 
to metabolise ethanolamine to use as a nitrogen source, while breakdown of 
acetaldehyde by eutE is dispensable for growth in minimal medium with 
ethanolamine as a nitrogen source (Fig 4.1, Fig 4.6)(3). Contrasting with 
these findings, deletion of eutE results in loss of fitness in AUM with 
ethanolamine (Fig 4.7). While the ethanolamine ammonia lyase is actively 
breaking down ethanolamine (Fig 4.7) in the eutE mutant this does not 
correlate with enhanced growth which suggests breakdown of acetaldehyde 
to acetyl Co-A is needed for growth on ethanolamine in the AUM. This data 
coupled with the high concentration of ammonium chloride in AUM (25mM) 
suggests that ethanolamine is utilised as an additional source of carbon in 
AUM and not nitrogen. Another possibility is that the acetaldehyde 
accumulation by deletion of eutE is causing a toxic effect. Despite the 
formation of the MCP, which is proposed to prevent the toxicity of 
acetaldehyde in ethanolamine metabolism, there is evidence for low level of 
intermediates being released (219, 220). Differential toxicity from 
ethanolamine metabolism in eutE deletion mutants has been observed in 
Salmonella depending on added carbon source in minimal medium. For 
example added ethanolamine prevents growth in the presence of succinate 
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(149). There is some evidence of growth inhibition with increasing levels of 
ethanolamine added to a eutE deletion mutant in AUM (see Appendix 4.3). 
Further Investigation into the production of acetaldehyde or acetyl-CoA 
would be needed to determine how ethanolamine is being utilised in AUM.  
An unexpected double mutation provided further evidence that ethanolamine 
utilisation stimulates growth by different mechanisms in nitrogen-limited M9 
Mod and AUM media (Fig 4.7a). When the U1ΔeutR mutant was created via 
P1 transduction, an additional insertion between between eutA and eutB was 
introduced to the strain. The CRZ-55 prophage previously seen in the widely 
used lab strain MG1655 (2, 204) and the KEIO parental strain BW25113 
(183, 211), is inserted between eutA and eutB. The prophage is inserted in 
reverse orientation to eut operon transcription (Appendix 4.2). As eutR has 
only one binding site in the eut operon, the presence of the prophage 
prevents the genes down-stream of eutA from being transcribed, including 
the ethanolamine ammonia lyase enzyme (141). As predicted, 
complementation of this mutant with the intact eutR ASKA clone did not 
rescue the phenotype in Mod M9 with ethanolamine after 24hrs, as the 
transcription of the ethanolamine ammonia lyase remains interrupted. 
However, incubation of eutR/pCA24N::eutR in Mod M9 with ethanolamine for 
longer than 30hrs shows restoration of growth. PCR analysis of the resulting 
strains shows that the prophage excises during prolonged nutritional stress 
(Fig 4.8). Natural excision of the CPZ-55 prophage has been described 
before in K12 BW25113 (221). In AUM, the growth phenotype was 
immediately restored from time zero with 10mM ethanolamine by eutR 
complementation (Fig 4.7a). There was minimal depletion of ethanolamine in 
the media suggesting this is not due to prophage excision during growth in 
AUM enabling transcription of eutBC and retention of the prophage in AUM 
after 30hrs was also confirmed by PCR (Appendix 4.5). The insertion of the 
prophage could result in the overexpression of the proximal portion of the 
operon, including eutD, eutG and eutE (5). These enzymes could interact 
with other metabolites in the media to convey this growth advantage. Due to 
the complexity of the media it is unclear which metabolite it could be utilising 
(185).  
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mRNA analysis showed that the eut operon was upregulated early (4-8hrs 
post inoculation) when cultured in growth in AUM (Fig 4.8). As the 
importance of rapid growth for UPEC survival in the bladder has been 
established, early induction of the eut operon is providing evidence of rapid 
metabolic adaption (50). Interestingly, with induction of the operon, coincided 
with upregulation of eutS, a shell protein involved with the formation of the 
ethanolamine BMC. This has also been seen previously in EHECs (3).  In 
this study BMC were visible in U1 when grown in AUM with 10mM 
ethanolamine. While visualisation of the Eut BMC in Salmonella and E. coli 
K-12 has been reported previously, there is no previous depiction of wild-
type Eut BMC in pathogenic E. coli that the author could find in the literature.  
When U1 and its associated strains were grown in Mod M9 with 0.5mM 
ethanolamine, physiological levels (Chapter3,(47)), the wild type, U1∆eutE 
and complement ∆eutE and ∆eutB grew to an OD600nm of 0.08, while the 
other knockout mutants did not display any growth. Growth of these strains 
starts at 4hrs post incubation as was seen when U1 is grown Mod M9 with 
10mM as the sole nitrogen source and therefore implies ethanolamine is 
being utilised to facilitate this small increase in OD600nm (Appendix 4.1a). In 
AUM there is a significant enhancement in growth, by 1.5x108 compared to 
the wild type strains in AUM and 0.5mM ethanolamine after 8 hours of 
growth (Fig 4.12). This directly contradicts the assertion that ethanolamine 
below 1mM does not support growth due to energy requirements needed for 
the metabolism of the ethanolamine (6).  
Previous work has found that deletion of the eut operon results in a fitness 
deficiency in E. coli in the UTI mouse model (17). In AUM, 10mM 
ethanolamine conferred a competitive growth advantage to U1 in vitro over 
an isogenic eutR mutant (Fig 4.13). E. coli engineered for enhanced amino 
acid uptake which conferring faster growth than the wild-type parental strain 
when cultured separately, lose their competitive advantage in co-culture 
(222). This is because enhanced amino acid uptake and subsequent amino 
acid metabolism results in ammonia leakage from the engineered cells which 
can be utilised by the competing wild-type bacteria. The preserved 
competitive advantage of U1 over ∆eutR and ∆eutB strains in AUM in the 
123 
 
presence of ethanolamine suggests that either ammonia is not being 
released from the cell when ethanolamine is utilised as a nitrogen source, or 
the competitive advantage conferred by ethanolamine metabolism in AUM is 
based on relief of carbon restriction rather than nitrogen restriction. The 
contrasting phenotype of ∆eutE mutants in nitrogen-restricted M9 Mod with 
ethanolamine (growth) and AUM with ethanolamine (no growth), and the 
preserved advantage of wild type U1 over the ∆eutE mutant in competitive 
co-culture in AUM with ethanolamine suggests that ethanolamine provides 
an additional carbon and energy source in AUM.   
When competition was assessed using physiological levels of ethanolamine 
(0.5mM), there was a small competitive advantage over the eutR mutants. 
Batch culture with physiological levels of ethanolamine in AUM provides a 
limited window to observe ethanolamine-conferred advantages given that E. 
coli uses it at a rate of 0.75mM/hour after a lag period of 4 hours in this 
medium (Fig 4.4).  Therefore, all ethanolamine would be consumed in the 
first 5 hours post inoculation compared to over 12 hours for 10mM 
ethanolamine, and onward metabolism of acetate and ethanol also 
concluding sooner. The advantage seen of 1.5x108 would be hard to 
distinguish in a competition assay.  Unlike this static model urine is 
continually being produced and in vivo would confer a continual supply of 
host-derived ethanolamine, passing into the bladder which could provide a 
competition advantage in vivo as seen  by Subashchandrabose et al. (9).  A 
continuous culture system would be required to replicate this.   
In conclusion, this study has found that UPECs isolated from urine can utilise 
ethanolamine as a sole nitrogen source. In the in vitro artificial urine medium 
model, ethanolamine also provides a competitive nutritional advantage for 
UPEC. However, there was evidence ethanolamine was being used as a 
carbon source in these conditions. Further work is required to confirm this. 
As a result, the nutritional supplement provides a competitive advantage to 
bacteria that can metabolise ethanolamine over bacteria that are unable to 
metabolise ethanolamine.  Therefore, ethanolamine in urine appears to be 
an important nutritional resource that infecting E. coli can access by 
microcompartment- mediated metabolism. 
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4.5 Appendix 
Appendix 4.1a. Automated growth curve of UPEC isolates U1-18 grown in ammonia free 
modified M9 (red) and ammonia free modified M9 supplemented with 10mM Ethanolamine 
as nitrogen source.  Values are Mean ± SEM. N=3. 
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Appendix 1b Automated growth curve of UPECs U19-36 grown in ammonia free 
modified M9(red) and ammonia free modified M9 supplemented with 10mM 
Ethanolamine as nitrogen source. Values are Mean ± SEM. N≥3.  
. 
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Appendix 4.1c Automated growth curve of UPEC isolated 37-79 grown in ammonia free 
modified M9(red) and  ammonia free modified M9 supplemented with 10mM 
Ethanolamine as nitrogen source. Values are Mean ± SEM. N≥3.  
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∆eutR 
∆eutE 
∆eutB 
U1 (WT)  
Appendix 4.2.eut operon of U1 and respective mutants. A U1 (wild type) B. U1∆eutB C. U1∆eutE D. 
U1∆eutR -prophage between eutA and eutB. Blue genes are eut operon genes; Red genes are 
kanamycin cassette insertion; Black genes of CPZ-55 prophage insertion.  
A. 
B. 
C. 
D. 
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Appendix 4.3. Growth of U1∆eutE in AUM with 0mM (Blue), 0.5mM (Green) and 10mM (Red) 
ethanolamine.  Growth is measured by A. OD
600
 and B CFU ml
-1
. Values are Mean ± SEM N ≥3. 
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Appendix 4.4 Growth of K-12 MG1655 in Mod M9 with 10mM ethanolamine. Values 
are Mean ± SEM N ≥3. 
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Appendix 4.5. Prophage does not excise when U1∆eutR/pCA24N::eutR is grown in 
AUM with 10mM Ethanolamine. A. Schematic of PCR over the kanamycin cassette 
border. B. Schematic of PCR over Prophage border. C. Gel image to confirm the 
presence of the kanamycin cassette in place of eutR. D. Gel image across the 
border of eutA and eutB E. Gel image over prophage border with eutB. Lanes: 1. 
AUM.1 2. AUM.2 3. AUM.3 4. AUM+10mM Eth.1 5. AUM+10mM Eth.2 6. 
AUM+10mM Eth.3. KE is the Keio strain JW2439-1. KR is Keio strains JW2430-1.  
P1 to K1 
P1:eutA_F to P2:eutB_R 
P1:cpz_R to P2:eutB_R 
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Chapter 5  Investigation into Ethanolamine 
Regulation of Virulence Factors in Uropathogenic E. 
coli. 
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5.1 Abstract  
Colonisation of a host is dependent on the pathogen's ability to acquire 
nutrients and express virulence factors. Ethanolamine can be used by 
bacteria as a nutrient as shown in Chapter 4 and has more recently been 
seen to regulate the expression of virulence genes in enteric pathogens (3, 
4, 6-8, 16, 168). The regulator eutR has been found to directly regulate the 
expression of the locus of enterocyte effacement (LEE) in EHEC and the 
Salmonella Pathogenicity island 2 (SPI-2) (7, 16). Additionally, ethanolamine 
has been seen to promote the expression of fimbriae in EHEC (8). Fimbriae 
are key colonisation factors for uropathogenic E. coli (UPEC) during urinary 
tract infection (UTI) and for long term colonisation of the gastrointestinal (GI) 
tract (9, 223). Recent expression analysis has shown that the eut operon is 
upregulated in vivo during UTI, therefore it can be hypothesised that 
ethanolamine may be a regulator of fimbriae and other virulence factors in 
UPECs in different environments (10, 17).  
In this study the ability of ethanolamine to promote virulence factors in 
UPECs was investigated in vitro.  The ability of two UPEC strains to produce 
fimbriae in the presence of ethanolamine was measured by agglutination and 
cell attachment assays. Ethanolamine did not affect these phenotypic assays 
of fimbriae; however ethanolamine appears to influence the ability of a eutR 
mutant of UPEC strain U1 to invade bacterial epithelial cells in vitro. Gene 
expression analysis in artificial urine media (AUM) detected differential 
expression of fimE and fimH type 1 fimbrial operon genes in UPEC strain U1 
in the presence of ethanolamine after 8 hours. Therefore, these studies 
suggest that ethanolamine may enhance fimbriae expression in AUM in 
some UPEC strains, however further studies would be needed to confirm 
these findings phenotypically.  
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5.2 Introduction  
The ability of a pathogen to colonise a host environment and cause infection 
is controlled by the acquisition of nutrients and the expression of virulence 
factors.  Ethanolamine which is derived from the host can be utilised by 
bacteria as a nutrient through its catabolism by a series of enzymatic 
reactions encoded in the ethanolamine utilisation (eut) operon (3, 13). A form 
of the 17-gene eut operon was first identified in Salmonella sp. is conserved 
across many species of bacteria (5, 224). Comparative genome analyses of 
pathogenic bacteria have associated the presence of the eut operon with the 
ability to cause infection (138, 167, 225). However, it is unclear whether this 
is due to ethanolamine metabolism itself or via another mechanism.  
Ethanolamine metabolism can promote a growth advantage for bacteria by 
being utilised as a nutrient as has been seen in E. coli (Chapter 4) (3). 
Induction of eut operon genes has also been detected in intracellular Listeria 
monocytogenes (170). L. monocytogenes are intracellular pathogens that 
invade epithelial cells as part of their infective cycle. Mutations within the 
ethanolamine ammonia lyase enzyme major subunit gene (eutB) reduces 
invasion of the epithelial cell line, Caco-2, by L. monocytogenes compared to 
the wild type, suggesting ethanolamine metabolism is important for cell 
invasion (170). Similarly, to L. monocytogenes, metabolism of ethanolamine 
provides a colonisation advantage for Salmonella enterica serotype 
Typhimurium (S. Typhimurium) in the GI tract. However the ability of S. 
Typhimurium to gain a growth advantage by ethanolamine metabolism in the 
anaerobic environment of the GI tract is dependent on the presence of 
inflammation derived tetrathionate as a final electron receptor (4, 172). 
Further work in S. Typhimurium reveals that while mutants in eutB and eutC, 
and therefore ethanolamine metabolism, were attenuated in colonising the 
mouse intestine, mutation in eutR, the operon regulator caused a greater 
colonisation defect when disseminating to other niches within the host such 
as within macrophages (16). This therefore suggests that the eut operon has 
a role in pathogenesis independent of ethanolamine metabolism.  
In S. Typhimurium and Enterohaemorrhagic E. coli (EHEC), the eut operon 
has been found to directly regulate virulence factors. S. Typhimurium is a 
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facultative intracellular pathogen, invading epithelial cells and macrophages 
in the GI tract to cause acute gastroenteritis. Survival within the macrophage 
is mediated by the expression of type three secretion systems (T3SS) that 
are encoded on Salmonella pathogenicity island 2 (SPI-2)(175). EutR was 
found to regulate expression of T3SSs by directly binding the promoter of 
ssrB, the regulator of SPI-2, and aid survival in macrophages and 
progression to systemic infection (16). Ethanolamine also mediates the 
expression of virulence factors in EHEC (6-8). EHECs bind to the epithelium 
of the intestine and form attaching and effacing (AE) lesions which destroy 
the structure of the villi and cause diarrhoeal disease (226). The majority of 
the genes needed for the formation of AE lesions are found on the locus of 
enterocyte effacement (LEE) Pathogenicity Island. EHEC preferentially bind 
to phosphatidylethanolamine phospholipids in enterocytes during infection, 
the source of ethanolamine in the host (214). Studies have found that 
ethanolamine upregulates genes involved in EHEC virulence which include 
ler, the transcriptional regulator of the LEE operon, histidine sensor kinases 
qseC and qseE,  and Shiga toxin stx (6). Expression of these virulence 
genes are independent of ethanolamine metabolism and later experiments 
confirmed that eutR directly binds to ler to regulate the transcription of the 
LEE operon (7). These studies however did reveal that micromolar 
concentrations of ethanolamine which induced the LEE operon did not 
induce expression of eutR, and therefore there may be an unidentified 
regulator that is responsible for ethanolamine-dependent virulence gene 
expression at these concentrations (6). More recently ethanolamine has 
been shown to promote expression of putative and characterised fimbriae 
which facilitate EHEC attachment to HeLa cells, however only a minority of 
the fimbriae induced by ethanolamine were regulated by eutR, again 
indicating the presence of another regulatory gene responding to 
ethanolamine (8). 
In addition to a role in intestinal infection the eut operon has found to be 
upregulated during UTI (17). Within the urinary tract E. coli utilise many 
virulence factors to colonise and cause infection. Adherence is crucial to E. 
coli survival in the urinary tract and as such uropathogenic E. coli (UPEC) 
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can encode at least 12 fimbriae in its genome (227). Type 1 fimbriae mediate 
the attachment and subsequent invasion required for formation of bacteria 
type communities in bladder epithelium cells (BECs) (41, 90, 91). Close 
association between infecting E. coli and host cells in urine has been seen in 
Chapter 3 of this thesis (Fig 3.8). Deletion of type 1 fimbriae results in 
colonisation defects in mouse urinary tract infection models (91).  
As the eut operon has been found to regulate expression of virulence factors 
in EHEC, and ethanolamine has been found to enhance growth of UPECs in 
vitro (Chapter 4), and regulate eut operon genes in infected urine (Chapter 
3), it can be hypothesized that ethanolamine may promote expression of 
virulence factors in UPECs to assist colonisation of the urinary tract, as has 
been seen in EHEC in the intestine. This study extends the findings from 
Chapter 3 and 4 and investigates whether ethanolamine could provide a 
regulatory role for virulence genes involved with UPEC pathogenesis. The 
ability of UPECs to produce fimbriae in the presence of ethanolamine were 
investigated using an agglutination assay and by measuring adherence to 
and invasion of the cell line HT1376. In addition, gene expression of U1 in 
AUM was examined for the expression of fimbriae.  
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5.3 Results 
5.3.1 Strain U1 binds erythrocytes via mannose resistant fimbriae 
During UTI bacteria attach to epithelial cells to colonise the urinary tract. 
They do this by forming fimbriae which bind to receptors on the Bladder 
Epithelial Cells (BEC) surface. To detect fimbriae formation by UPECs, 
bacteria were incubated with guinea pig erythrocytes (Chapter 2) to measure 
haemagglutination. The UPEC strains U1, U13, U17 and U38 were grown in 
fimbriae-inducing conditions (statically) in LB media in the presence or 
absence of 10mM ethanolamine. U1, U1∆eutB, U1∆eutR and U38 have high 
haemagglutination titres (23-4) when grown in LB compared to U13 and U17 
where haemagglutination does not occur (Fig 5.1b). Growth in the presence 
of ethanolamine did not cause a significant difference in the ability of the 
UPECs to cause haemagglutination, however there does appear to be a 
decrease in the agglutination ability of U1 in the presence of ethanolamine 
(Mann Whitney-U test) (Fig 5.1b).  
To assess whether the fimbriae produced by U1, U1∆eutB, U1∆eutR and 
U38 were mannose sensitive, which is characteristic of type 1 fimbriae, the 
bacterial dilutions were incubated with 4% mannose before the erythrocytes 
were added. After overnight incubation with erythrocytes, U38 was unable to 
bind to erythrocytes and unable to cause haemagglutination (Fig 5.1c). U1, 
U1∆eutB and U1∆eutR were however still able to bind to erythrocytes after 
incubation with 4% mannose indicating the fimbriae expressed by U1 are 
mannose resistant (Fig 5.1c).  
In parallel to the haemagglutination assay, the expression of type I fimbriae 
was tested with a yeast agglutination assay. The UPECs were grown 
overnight in fimbriae-inducing conditions with and without 10mM 
ethanolamine. Bacteria were incubated with 1% Saccharomyces cerevisiae 
and agglutination was determined after 10mins as being positive (+) or 
negative (-). Agglutination was only detected in U38 and this was prevented 
with the addition of mannose (Table 5.1). This suggest that U38 is the only 
strain to produce mannose sensitive fimbriae in these conditions confirming 
the observation shown by the haemagglutination assay. 
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Figure 5.1 UPECs bind to Guinea Pig red blood cells. A. Photo representation 
of haemagglutination. Negative PBS/PBS+4% mannose controls are circled in 
red. Haemagglutination titre of bacteria grown statically overnight in LB or 
LB+10mM ethanolamine and incubated with: B defibrinated guinea pig 
erythrocytes; C defibrinated guinea pig erythrocytes and 4% mannose. Values 
are Mean ± SEM N=4 
B 
C 
A 
U 1 
U 1ΔeutB 
U1ΔeutR 
U13 
U17 
U38 
+ 4% mannose  
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5.3.2  
Table 5.1 Yeast Agglutination Assay. + indicates positive agglutination and – 
indicates negative agglutination after 10minutes incubation with 1% Saccharomyces 
cerevisiae. Values are Mean ± SEM N=3 
 
      4% Mannose 
Bacterial 
Strain  LB LB+10mM EA LB LB+10mM EA 
U1 - - - - 
U1ΔeutB - - - - 
U1ΔeutR - - - - 
U13 - - - - 
U17 - - - - 
U38 + + - - 
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5.3.3 Ethanolamine does not affect E. coli adhesion to human 
bladder epithelial cell line HT1376 
To assess whether utilising ethanolamine alters the ability of U1 and U13 to 
attach to epithelium, a cell culture model was set up using the bladder 
epithelial carcinoma cell line, HT1376. The bacteria were cultured with the 
epithelial cells for 3 hours before the epithelial cells were removed, lysed and 
the lysate containing attached bacteria plated on agar. Comparing the CFU 
ml-1 of U1 and the eut knock out mutants, U1∆eutB and U1∆eutR, there was 
no significant difference in the ability of the mutants to colonise the epithelial 
cells compared to the wild type (ANOVA) (Fig 5.2a). However, there was a 
significant difference in adherence of U1 and the eut mutants compared to 
U13 and HM605, a well-studied adherent-invasive E. coli strain, which was 
used as a positive control in this study (p<0.001, 1-way ANOVA) (Fig 5.2). 
This increase in adherence is not attributed to an increase in growth rate, as 
all bacteria grow to the same OD600nm after 3-hour incubation in DMEM 
(Appendix 5.1). Comparing the difference in adherence within strains, the 
metabolism of ethanolamine does not appear to enhance adherence to 
epithelial cells. There was no significant difference in the ability of individual 
strains to bind with the addition of ethanolamine to the cell culture (Mann 
Whitney-U test) (Fig 5.2). This suggests that the ability of the E. coli to 
produce fimbriae in the presence of epithelial cells is unaffected by the ability 
to detect or metabolise ethanolamine.  
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ethanolamine. Comparison by Mann Whitney U. Values are Mean ± SEM N=3 
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5.3.4 UPEC do not easily invade bladder epithelial cells HT1376 
During infection UPEC evade the host immune system by invading epithelial 
cells and replicating to form intracellular bacterial communities, and this is 
facilitated by the formation of fimbriae (90). Therefore the ability of UPEC 
strains to invade BECs was measured using a BEC cell lysis model similar to 
section 5.3.2 with an additional step in which adherent bacteria were killed 
with gentamicin prior to lysis (Chapter 2). Comparing the CFU ml-1 of 
bacteria that invade the epithelial cells, there is no significant difference in 
the ability of different bacterial strains to invade the BECs (ANOVA), however 
U13 and the adherent invasive E. coli HM605 appear to invade in higher 
numbers compared to U1 strains. When ethanolamine was added to the 
incubation media, no significant difference was calculated between DMEM 
and DMEM with 10mM ethanolamine in most strains, however U1∆eutR 
there was a decrease in CFU ml-1 recovered when incubated in the presence 
of ethanolamine (p<0.05, Mann Whitney-U test) (Fig 5.3).  
 
U1 U1eutB U1eutR U13 HM605
1
10
100
1000
10000
0mM Eth
10mM Eth*ns ns
ns ns
C
F
U
 m
L
-1
Figure 5.3 Invasion of E. coli in HT1376. A. CFU ml
-1
 of bacteria invasion of HT1376 after 
4 hours incubation in low glucose DMEM with and without 10mM ethanolamine. 
Comparison by Mann Whitney U. Values are Mean ± SEM N=3 
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5.3.5 Expression of Fimbriae in Artificial Urine Medium (AUM) 
In Chapter 4 E. coli metabolism of ethanolamine was assessed for its ability 
to cause a growth advantage in AUM. RNA analysis showed that the eut 
operon was upregulated during growth in AUM with ethanolamine, with 
highest expression after 4 hours and 8 hours of growth (Chapter 4, Fig 4.7). 
However it was not assessed whether expression of the eut operon 
regulated the expression of genes known to be involved with virulence. As 
there is evidence of ethanolamine regulating epithelial invasion (Fig 5.3) 
which is mediated by type 1 fimbriae (90), expression of the fim operon that 
encode type 1 fimbriae was measured in RNA from U1 and U1∆eutR grown 
in AUM (Chapter 4). 
The expression of fimE, the phase variation recombinase which regulates 
expression of the fim operon, and fimH, the adhesion protein that tips the 
fimbriae and facilitates binding to mannose residues on epithelial cells, was 
detected in U1(40, 228). In AUM the expression of fimE and fimH was 
highest after 8 hours incubation, with 10mM ethanolamine (Fig 5.4 a). The 
expression of fimE after 8 hours with 10mM ethanolamine was not 
significantly different compared to 4hrs and 24hrs incubation (Kruskal-Wallis 
test). However there was a significant difference in fimE expression when the 
effect of different concentrations of ethanolamine was measured at 8 hours 
(Kruskal-Wallis test, p<0.05) (Fig 5.4a).  
There was a significant 50-fold increase in fimH expression between 4 hours 
and 8 hours when U1 was grown in 10mM ethanolamine (Kruskal-Wallis test, 
p<0.05) (Fig 5.4a), and similarly to fimE there was a significant different in 
fimH expression when the effect of different concentrations of ethanolamine 
was measured at 8 hours (Fig 5.4 a). The expression of fimH was measured 
in the eutR knockout mutant at 8 hours, when expression of fimH appears to 
be highest in U1. A 30-fold decrease in expression in the U1∆eutR was 
measured compared to U1 when grown in AUM with 10mM ethanolamine, 
this difference however was not significant (Mann-Whitney U) (Fig 5.4 b). 
These results suggest that ethanolamine does affect type 1 fimbriae 
expression in AUM and this may be at least partly mediated by eutR.  
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Figure 5.4 Expression of type 1 fimbrae A. Relative expression of fimE and fimH in U1 
after 4, 8 and 24hours growth in AUM with different concentration of ethanolamine. B. 
Relative expression of fimH in U1 and U1∆eutR 8 hours growth in AUM with different 
concentration of ethanolamine. Relative expression to the geometric mean of 
housekeeper genes rrsA and gyrB.  Comparison by 1-way ANOVA (straight line) or Mann 
Whitney U (edged line). Values are Mean ± SEM N=3. 
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5.4 Discussion 
Pathogens express virulence factors to colonise and acquire nutrients within 
the host environment to cause infection. Ethanolamine is known to be 
metabolised by enteric pathogens to provide additional nutritional support in 
the GI tract (3, 4). Previously in this thesis it has been shown that 
ethanolamine can be metabolised by UPEC to provide them with a nutritional 
advantage in vitro (Chapter 4). However, there is growing research 
demonstrating the ability of ethanolamine to act as a signalling molecule to 
regulate virulence (6, 16). EutR, the regulator of the eut operon has been 
found to directly regulate virulence factors in EHEC (6-8). One virulence 
mechanism that has been shown to be regulated by ethanolamine in EHEC 
is the expression of fimbria proteins, although EutR is not always the 
regulator involved (8). As there is a recently recognised role for ethanolamine 
in regulating pathogenicity of UPEC (10, 17), and fimbriae are crucial to the 
successful colonisation of the urinary tract (93, 94), it was hypothesised in 
this thesis that ethanolamine regulates expression of fimbriae in UPECs. 
Furthermore, ethanolamine regulates the locus of enterocyte effacement 
(LEE) operon in EHEC, which mediates attachment to host cells and the 
characteristic attaching and effacing (A/E) lesions affecting host cells, 
respectively (7, 8). It was therefore hypothesised that equivalent properties of 
cell attachment and invasion in UPECs could be similarly regulated. 
Type1 fimbriae are the most studied fimbriae expressed by UPECs. They 
enable the adhesion of bacteria to mannose moieties on the surface of BECs 
and have been found to facilitate the invasion of BECs (87, 90). Bacterial 
adherence to host cells was visible in infected urines collected in this study 
and expression of fimH was detected in half the UPEC RNA analysed in 
Chapter 3 (Fig 3.8). Additionally, the ability to express type 1 fimbriae in vitro  
has been shown to increase colonisation of the murine urinary tract (38). 
Through agglutination assays it was determined that UPEC strains U1 and 
U38 express fimbriae in vitro and that while those expressed by U38 were 
mannose sensitive, those in U1 were not (Fig 5.1 and Fig 5.3). There was no 
apparent effect of ethanolamine addition to LB growth medium in this 
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phenotypic assay. If time had permitted this experiment would have been 
repeated with AUM-grown cells.  
RT-PCR provided evidence of ethanolamine the significant induction of Type 
1 fimbria genes fimE and fimH after eight hours in AUM with 10mM 
ethanolamine compared to when ethanolamine was not added (Fig 5.4a). 
fimH induction by 10mM ethanolamine was greatly reduced by eutR 
knockout, but not abolished, suggesting a role for eutR as well as another 
regulatory circuit in this process, however this finding was not significant (Fig 
5.4b). Further experimentation looking at gene expression when grown in 
static conditions examining the expression of the fim operon in the other U1 
mutants would further this area of study.  
The ability of UPECs to attach and invade bladder epithelial cell line HT1376 
was measured in the presence of ethanolamine. Incubation in ethanolamine 
for 4 hours did not affect the ability of UPECs to bind to the epithelial cells in 
the assay used (Fig 5.3). Additionally, mutations in eutB and eutR did not 
affect the ability of UPEC strain U1 to bind to HT1376 in the presence or 
absence of ethanolamine, suggesting that ethanolamine does not affect 
bacterial attachment to epithelial cells. Surprisingly, however, U1∆eutR 
demonstrated a significant decrease in the ability to invade epithelial cells 
when ethanolamine was supplemented (Fig 5.4). If this defect was due to eut 
operon inactivation alone, this would imply that the ability to sense and/or 
metabolise ethanolamine is important for the invasion of epithelial cells, but 
only when ethanolamine is present, which is difficult to explain. However, this 
phenotype is only present in U1∆eutR and not U1∆eutB which suggest 
invasion is independent of ethanolamine metabolism. A more likely 
explanation is that eutR is a direct or indirect repressor of another 
ethanolamine sensor or regulator outside the eut operon that in turn 
represses a bacterial factor required for invasion, or eutR and the 
unidentified ethanolamine sensor co-regulate an invasion factor. This is 
compatible with data collected from EHEC indicating the existence of an 
unidentified regulator responsible for ethanolamine-dependent virulence 
gene expression and expression of putative and characterised fimbriae (6, 
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8). Experimentation with the complemented eutR mutant to examine this 
further was not possible in the time available.  
In summary, RT-PCR evidence was found supporting the hypothesis that 
induction of genes encoding Type 1 fimbriae in a UPEC strain are influenced 
by ethanolamine. Phenotypic evidence for the induction of Type 1 fimbriae by 
ethanolamine in UPEC strains was not found, and mutation of the eut operon 
had no effect on haemagglutination titres. However, haemagglutination 
experiments were not carried out in AUM media where high expression of 
the eut operon is detected when ethanolamine is added (Chapter 4, Fig 4.9). 
Ethanolamine and eut operon mutants did not affect the attachment of 
UPECs U1 and U13 to attach to the uroepithelial cell line HT1376. However, 
U1∆eutR mutation abolished cell invasion in the presence of ethanolamine, 
suggesting an indirect role for the eut operon in uroepithelial cell invasion. 
Future experiments would be required to extend this area of investigation. 
This includes experimentation with the complemented mutant strains to 
confirm the phenotypes seen in this chapter. Additionally, measuring fimbriae 
expression by qRT-PCR and phenotypic assay when grown in a static 
culture of AUM with ethanolamine to determine whether ethanolamine 
influences expression of fimbriae in conditions similar to those seen in the 
bladder. In this study the ability of UPEC adhere and invade bladder 
epithelial cells was measured after 4 hours co-incubations. However, from 
qRT-PCR data this this chapter fim genes are upregulated after 8 hours 
growth in AUM with ethanolamine. Therefore, the ability of U1 to attach to 
HT1376 should be measured after 8 hours pre-growth in AUM with 
ethanolamine. Finally, further investigation in UPEC strains that have 
increased attachment potential such as U38 that produce mannose sensitive 
fimbriae, or U13 that has greater binding ability in the in vitro cell assay could 
enhance investigation into ethanolamine regulation of fimbriae.  
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5.5 Appendix 
 
 
Appendix 5.1. Growth of E. coli strains in Low glucose DMEM with and without 
10mM ethanolamine. Values are Mean ± SEM N=3 
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Urinary tract infections (UTIs) are a significant burden on healthcare systems 
worldwide and are primarily caused by Uropathogenic E. coli (UPEC) which 
account for 75% of all UTIs (1, 11). There is a lack of conserved virulence 
factors in UPEC, unlike other pathogenic E. coli strains (38). However, 
pathogenesis studies into UPEC are shifting focus from putative 
uropathogenic virulence factors and are beginning to investigate the role of 
adaptive metabolism (12, 45).  Ethanolamine can be metabolised by E. coli 
as a source of carbon and nitrogen and has been linked to enteric bacterial 
pathogenesis by providing pathogenic bacteria with a competitive advantage 
(3, 4, 170).  Additional studies have found that ethanolamine can be utilised 
as a regulatory molecule, controlling expression of virulence factors in EHEC 
(6-8). Recently the role of the ethanolamine utilisation (eut) operon in the 
urinary tract has been investigated (10, 17). Studies have found that the eut 
operon is upregulated in human UTI and promotes colonisation in a murine 
UTI model.  However, it is unknown whether the eut operon is facilitating the 
metabolism of ethanolamine in the urinary tract or is sensing ethanolamine 
as a signal used to regulate colonisation factors, both functions have been 
seen in enteric pathogenesis. In this thesis the role of ethanolamine 
utilisation by UPEC in the urinary tract was investigated. The overall aim of 
this thesis was to determine whether ethanolamine is metabolised in the 
urine, whether metabolising ethanolamine confers a competitive advantage 
for UPECs, and whether other virulence factors are regulated by 
ethanolamine. 
The initial aim of this study was to characterise clinically collected UPECs to 
determine whether they were metabolically active in urine (Chapter 3). Within 
urine, peptides and amino acids are the main source of carbon (49). UPECs 
have adapted to metabolise amino acids for acetogenic growth (58). The 
most abundant amino acid in urine, D-serine (0.38mM) is preferentially 
utilised by E. coli in vitro (1, 205). Similarly, ethanolamine can be 
metabolised by bacteria as a source of carbon by producing acetyl-CoA and 
acetate (148, 206). Analysis of 52 infected urine samples collected from Cork 
University Hospital, detected ethanolamine in urine at an approximate 
concentration of 0.57mM. This is more abundant than D-serine in urine 
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(137). In the intestine ethanolamine is believed to derive from epithelial cell 
turnover and other microbes, however in the bladder uroepithelial cell turn-
over is 50-fold slower and therefore would not appear to provide a viable 
source of ethanolamine in the urine. A characteristic of UTI, however, is the 
large influx of neutrophils, driven by expression of IL-8. It was hypothesised 
in this study that immune cells could provide the ethanolamine detected in 
urine. However, no correlation was detected between cytokine expression 
and urinary ethanolamine concentration, and similar ethanolamine levels 
were detected in healthy control urine samples with no white cells. This 
suggests ethanolamine in the urine is more likely to derive from excretion 
from the kidneys. Cytospin and TEM showed that E. coli adheres tightly to 
host cells in infected urine suggesting another possible source for 
ethanolamine. Previous studies with EHEC have found that they 
preferentially bind phosphatidylethanolamine (PE) rather than other 
phospholipids (214). E. coli binding PE on urinary neutrophils or epithelium 
could be facilitating local ethanolamine metabolism without increasing urinary 
ethanolamine. However further studies would be needed to examine this. 
Genomic analysis of UPEC strains (Chapter 3) isolated at Cork University 
Hospital  showed that the eut operon was conserved in all 47 strains, 
however the D-serine tolerance locus (dsdCXA) needed to metabolise D-
serine was only present in 53% of the UPEC (216).  mRNA analysis 
conducted in this thesis provides evidence that the eut operon is upregulated 
in UPEC-infected urine, which supports previous published findings (17). 
However, a novel finding in this thesis was that the degree of upregulation of 
the eutB gene encoding the first step in ethanolamine metabolism correlates 
with the concentration of ethanolamine detected in urine. This suggests 
ethanolamine is being actively metabolised during UTI rather than just acting 
as a regulatory molecule.  In urine, UPECs show some signs of nitrogen 
stress, as they are unable to utilise urea, the primary source of nitrogen in 
urine and are known to be utilising amino acids for gluconeogenesis (12, 45). 
Therefore, it is unclear whether metabolism of ethanolamine in urine could 
provide E. coli with a nitrogen source, a carbon source, or both. 
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To explore how metabolised ethanolamine is utilised in urine, growth of 
UPECs with ethanolamine was assessed in vitro (Chapter 4).  Most studies 
to date have used K12-laboratory strains and enteric pathogenic E. coli to 
investigate ethanolamine metabolism in E. coli (3, 144, 206). However, this 
thesis provides evidence that UPECs actively metabolise ethanolamine in 
vitro to provide a growth advantage. It has been documented that E. coli can 
utilise ethanolamine as a sole nitrogen source, however it is unclear in which 
circumstances ethanolamine can be used as a sole carbon source by E. coli 
(3, 218). An early study showed that ethanolamine can be used as a carbon 
source by some E. coli strains (but not others) at relatively high 
concentrations (82mM)(218). A more recent study was unable to show 
ethanolamine use as a carbon source in EHEC (3). It has been shown that 
other enzymes of central metabolism, such as the Acetyl-CoA synthetase 
(Acs), are required for the use of ethanolamine use as a carbon source in 
Salmonella, and a full TCA cycle is known to be required by E. coli in UTI 
(12, 147, 148). Therefore, mutations or global regulatory differences outside 
the eut operon could explain why ethanolamine cannot be used as a carbon 
source by all E. coli  
In this study (Chapter 4) evidence is provided that 10mM ethanolamine can 
be used by UPEC strains as a sole nitrogen source in minimal (Mod M9) 
media, and eutR (operon regulator) and eutB (major component of 
ethanolamine ammonia lyase) are essential for this. Additionally, it was found 
that ethanolamine could be used at the physiological concentration found in 
urine  (0.5mM) by a UPEC strain as a nitrogen source to provide a growth 
advantage, contradicting the published assertion that ethanolamine cannot 
support growth at concentrations lower than 1mM (6). Again, eutR and eutB 
were essential for this.  UPEC culture in an artificial urine medium (185) 
(AUM) showed upregulation of eut operon enzyme and shell protein genes 
and growth enhancement when 10 mM ethanolamine was added, with the 
appearance of microcompartment structures in the cytoplasm.  However, in 
AUM, unlike ModM9 medium, eutE (acetaldehyde dehydrogenase) was 
essential for growth enhancement with ethanolamine. Ethanolamine 
ammonia lyase activity alone, releasing ammonia and acetaldehyde, did not 
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appear to provide UPEC with a growth enhancement in AUM, unlike in 
ModM9 minimal medium.  A need for acetaldehyde to be further metabolised 
to acetyl-CoA and acetate to provide a growth advantage suggests that 
ethanolamine could be acting as a carbon source in this medium. Previous 
studies have found that the accumulation of acetaldehyde can cause a toxic 
effect and prevent cell growth, therefore the production of acetaldehyde and 
the viability of bacterial cells in culture would be required to exclude 
acetaldehyde toxicity as a cause for this phenotype. 
In the K12 strains MG1655 and BW25113, the prophage CPZ-55 is inserted 
between eutA and eutB of the eut operon (204, 211). The CPZ-55 prophage 
inserted in this region is transcribed in the reverse orientation compared to 
the eut operon. As there is only one promotor of the eut operon it is assumed 
that the genes downstream of the insert are not transcribed (see Fig 4.1), 
therefore ethanolamine cannot be metabolised (2, 141, 143). In this thesis a 
novel prophage was identified eutA and eutB in UPEC strain U71 (Chapter 
3). Additionally, the CPZ-55 prophage was introduced into the U1 genomes 
during transduction forming U1∆eutR (Chapter 4). Investigations into E. coli 
prophage have found that some prophage including CPZ-55 excise naturally 
at very low rates of less than 1 per 100,000 cells (221). Within this thesis it 
was found that the prophage can excise from the eut operon when faced with 
prolonged nutritional stress in Mod M9 (Chapter 4). Interestingly, the 
prophage does not appear to excise from complemented U1 in AUM despite 
the growth phenotype being restored. This phenomenon remains to be 
explained; it is proposed that the enzymes transcribed from the proximal 
region of the operon interact with other metabolites in the cytoplasm as a 
complete BMC cannot be formed. An additional hypothesis is that eutR might 
be regulating other metabolic pathways to provide a growth advantage. 
Further studies in this area would be needed to explain this finding. 
The Eut microcompartment is a proteinaceous structure that encases the 
metabolism of ethanolamine (5). The presence of the Eut bacterial 
microcompartment (BMC) is hypothesised to protect the bacteria from the 
toxic effect of acetaldehyde (15). Additionally, the Eut BMC has been 
proposed to concentrate enzymes and intermediates to speed up the 
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transition of acetaldehyde to the non-toxic acetyl-coA (14). The genes that 
encode the Eut BMC shell proteins have been identified as core genes in 
Salmonella and E. coli, however there are limited images of Eut BMC and 
these are in E. coli K-12(5, 164).  In this thesis, eutS, one of the shell 
proteins was highly upregulated in AUM with 10mM ethanolamine and TEM 
confirmed the presence of BMC-like structures in the bacterial cytoplasm. To 
the author’s knowledge, the images presented in this thesis are the first 
images of native eut BMC in UPEC E. coli and suggest AUM facilitates 
ethanolamine induction of microcompartments (Fig 4.10b). 
Work in Chapter 4 has provided evidence that ethanolamine metabolism 
promotes a growth advantage and also a competitive advantage in co-culture 
for UPEC in AUM, in vitro. Studies to date have shown that activation of the 
eut operon occurs in human urinary tract infection and knockout impairs 
fitness in a murine model of urinary tract infection. However, no study has 
shown this is because of ethanolamine metabolism in the urinary tract (10, 
17). Studies using UPEC mutants interrupting key parts of the ethanolamine 
metabolic pathway, such as those constructed in this thesis, could be used to 
determine which parts of ethanolamine metabolism are important for UTI in 
vivo, and could determine whether utilisation of ethanolamine as a nitrogen 
source or a carbon source is key to colonisation.  
A secondary aim in this thesis was to determine whether the eut operon can 
regulate the expression of putative urovirulence gene in UPECs (Chapter 5). 
Metabolism of ethanolamine can produce acetyl phosphate which can be 
converted to acetate (148). There is evidence to show that acetyl phosphate 
influences cell division, expression of flagella, type 1 fimbriae, capsular 
proteins, biofilm and stress response in E. coli (205). While there is a lack of 
conserved virulence factors in UPEC, putative urovirulence factors such as 
fimbriae, are crucial for the colonisation of the murine urinary tract, and 
flagella are important for the ascent of bacteria into the kidney to cause 
disease (44, 90, 91). In addition to metabolism, the eut operon directly 
regulates the expression of virulence factor in enteric pathogens (7). This 
include regulating the Locus of Enterocyte Effacement (LEE) operon, which 
encode genes involved with characteristic virulence genes for EHEC 
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pathogenesis (6, 7). Work by the same group found that ethanolamine 
helped regulate putative fimbriae in EHEC (8). Cytospins in Chapter 3 of this 
thesis presents evidence that bacteria adhere to the surface of host cells and 
fimbriae genes are expressed in infected urine (Fig 3.8). In this study there is 
evidence of fim operon expression in U1 grown in AUM at time points where 
ethanolamine is being actively metabolised, however as the expression of 
fimH was still upregulated in U1ΔeutR in the presence of ethanolamine, fim 
expression cannot be assumed to be regulated by the eut operon alone or by 
metabolism of ethanolamine. In vitro investigation using the bladder epithelial 
cell line HT1376 found that ethanolamine incubation did not enhance the 
adhesion of two selected UPEC strains. However, ethanolamine negatively 
affected the ability of U1ΔeutR mutants, in principle unable to sense or 
metabolise ethanolamine, to invade the epithelial cells (See Fig 5.3). 
Therefore, a secondary ethanolamine sensor/regulator outside of the eut 
operon could be responsible for an effect of ethanolamine on epithelial cell 
invasion and expression of the fim operon. The presence of a secondary 
ethanolamine sensor has previously been proposed in EHEC, and more 
work would be needed to confirm this hypothesis in UPEC (6).  
In conclusion, this thesis has provided evidence that ethanolamine is utilised 
as a nutrient source by UPECs in different in vitro environments. It has 
shown that ethanolamine is present in the urine (0.57mM) and that this level 
of ethanolamine is sufficient to confer an in vitro growth advantage and the 
eut operon is upregulated in relation to metabolising ethanolamine at this 
level. Investigation using artificial urine medium suggests that ethanolamine 
may provide an additional source of carbon in urine, through 
microcompartment mediated metabolism of ethanolamine. Additionally, this 
study has found that the border between eutA and eutB in E. coli is prone to 
prophage insertion, therefore care is needed in future experimentation into 
ethanolamine metabolism to ensure this site is not compromised.  This study 
has provided evidence that ethanolamine does not promote expression of 
fimbriae in the UPEC strain U1 to enhance attachment to epithelial cells in 
the conditions tested.  However, ethanolamine has a negative impact on U1's 
ability to invade BEC when the eut operon is inactivated, suggesting a 
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regulatory circuit depending on ethanolamine outside the eut operon.  The 
findings presented in this thesis supports the hypothesis that ethanolamine 
can be utilised by UPEC as a nutrient to provide a competitive growth 
advantage in UTIs.  Further studies are needed to confirm a role for 
ethanolamine as a signalling molecule in UPEC pathogenesis. 
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